[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4841
1. Bolli M, Schultz-Thater E, Zajac P, Guller U, Feder C, Sanguedolce F, Carafa V, Terracciano L, Hudolin T, Spagnoli GC, Tornillo L: NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study. Int J Cancer; 2005 Jul 20;115(6):960-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study.
  • The characterization of the expression pattern of different families of cancer/testis (C/T) antigens in different tumors, at the protein level, might be of relevance in the development of multiantigen vaccine preparations for active specific immunotherapy.
  • Expression in >10% of cases was detectable in melanoma and basalioma (31.6 and 18.2%, respectively), large cell carcinomas and adenocarcinomas of the lung (17.8 and 10.5%, respectively), stomach adenocarcinomas of the intestinal type (13.2%), pT2-4 bladder TCC (18.2%), nonseminomatous carcinomas of the testis (10.4%) and liposarcomas (15.4%).
  • Simultaneous expression of NY-ESO-1/LAGE-1 and MAGE-A C/T antigens was then addressed in a TMA where 101/845 and 73/845 samples (12 and 8.6%, respectively) showed evidence of MAGE-A or NY-ESO-1/LAGE-1 specific staining, respectively.
  • Discrepancies in the expression of NY-ESO-1/LAGE-1 and MAGE-A were conspicuously detectable in squamous cell carcinomas of the skin (MAGE-A positive but NY-ESO-1/LAGE-1 negative) and in liposarcomas (NY-ESO-1/LAGE-1 positive, but MAGE-A negative).
  • Taken together, these data suggest novel areas of application of C/T antigens targeted active specific immunotherapy possibly based on multiantigen vaccine preparations.
  • [MeSH-major] Antigens, Neoplasm / immunology. Antigens, Neoplasm / metabolism. Membrane Proteins / metabolism. Neoplasms / immunology. Testis / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15751033.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / CTAG1B protein, human; 0 / Membrane Proteins
  •  go-up   go-down


2. Biancone L, Orlando A, Kohn A, Colombo E, Sostegni R, Angelucci E, Rizzello F, Castiglione F, Benazzato L, Papi C, Meucci G, Riegler G, Petruzziello C, Mocciaro F, Geremia A, Calabrese E, Cottone M, Pallone F: Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut; 2006 Feb;55(2):228-33
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study.
  • BACKGROUND AND AIMS: The widespread use of anti-tumour necrosis factor alpha antibody (Infliximab) in Crohn's disease (CD) raises concerns about a possible cancer risk in the long term.
  • Cases and controls were matched for sex, age (+/-5 years), site of CD, age at diagnosis (+/-5 years), immunosuppressant use, and follow up.
  • In the CD-IFX group, there was one cholangiocarcinoma, three breast cancers, one skin cancer, one leukaemia, one laryngeal cancer, and two anal carcinomas.
  • Among the 7/404 (1.73%) CD-C, there were three intestinal adenocarcinomas (two caecum, one rectum), one basalioma, one spinalioma, one non-Hodgkin's lymphoma, and one breast cancer.
  • Age at diagnosis of neoplasia did not differ between groups (CD-IFX v CD-C: median 50 (range 40-70 years) v 45 (27-72); p=0.50).
  • CONCLUSION: In our multicentre matched pair study, the frequency of a new diagnosis of neoplasia in CD patients treated with Infliximab was comparable with CD patients who had never received Infliximab.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Crohn Disease / drug therapy. Gastrointestinal Agents / adverse effects. Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 Feb 26;350(9):934-6 [14985492.001]
  • [Cites] Gut. 2005 Aug;54(8):1121-5 [16009685.001]
  • [Cites] Gut. 2004 Jun;53(6):849-53 [15138212.001]
  • [Cites] Gastroenterology. 2004 May;126(6):1574-81 [15168368.001]
  • [Cites] Gastroenterology. 1979 Oct;77(4 Pt 2):843-6 [467941.001]
  • [Cites] Gut. 1984 Oct;25(10):1124-5 [6479689.001]
  • [Cites] Am J Gastroenterol. 1985 Dec;80(12):978-82 [3000170.001]
  • [Cites] Lancet. 1990 Aug 11;336(8711):357-9 [1975343.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):2015-9 [2004319.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):2051-5 [1717133.001]
  • [Cites] Gastroenterology. 1994 Mar;106(3):643-8 [8119535.001]
  • [Cites] Gastroenterology. 1994 Dec;107(6):1675-9 [7958678.001]
  • [Cites] Lancet. 1996 Jan 27;347(8996):215-9 [8551879.001]
  • [Cites] Gastroenterology. 1997 Apr;112(4):1169-78 [9098000.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1029-35 [9321530.001]
  • [Cites] Gastroenterology. 1998 Jul;115(1):182-205 [9649475.001]
  • [Cites] N Engl J Med. 1999 May 6;340(18):1398-405 [10228190.001]
  • [Cites] Gastroenterology. 1999 Oct;117(4):761-9 [10500056.001]
  • [Cites] Hepatology. 2005 Jan;41(1):5-15 [15690474.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):687-94 [15765404.001]
  • [Cites] Gut. 2005 May;54(5):617-22 [15831904.001]
  • [Cites] Gastroenterology. 2005 Jun;128(7):1812-8 [15940616.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1433-7 [10579985.001]
  • [Cites] Inflamm Bowel Dis. 2000 Feb;6(1):8-15 [10701144.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):647-53 [10982757.001]
  • [Cites] Gut. 2000 Oct;47(4):514-9 [10986211.001]
  • [Cites] Am J Gastroenterol. 2000 Sep;95(9):2308-12 [11007233.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):854-62 [11241255.001]
  • [Cites] Gastroenterology. 2001 Nov;121(5):1080-7 [11677199.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):72-7 [11781282.001]
  • [Cites] Lancet. 2002 May 4;359(9317):1541-9 [12047962.001]
  • [Cites] Gastroenterology. 2002 Jun;122(7):1808-14 [12055588.001]
  • [Cites] Cancer Invest. 2003 Jun;21(3):452-64 [12901291.001]
  • [Cites] Colorectal Dis. 2003 Sep;5(5):490-5 [12925087.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):19-31 [14699483.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Feb 1;19(3):287-93 [14984375.001]
  • [Cites] N Engl J Med. 2004 Feb 26;350(9):876-85 [14985485.001]
  • [Cites] Gut. 2004 Jun;53(6):780-2 [15138201.001]
  • (PMID = 16120759.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Gastrointestinal Agents; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab
  • [Other-IDs] NLM/ PMC1856527
  •  go-up   go-down


3. Bostock-Ling N: Excising basal cell carcinoma in general practice. Aust Fam Physician; 2006 Jul;35(7):558-60
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excising basal cell carcinoma in general practice.
  • BACKGROUND: Currently there is much interest in the general practice management of basal cell carcinoma (BCC).
  • METHODS: A retrospective audit of histopathology reports from 91 excisions of BCCs.
  • RESULTS: Thirty-nine percent of BCCs in this series were located on the head or neck, compared with 75-94% from other series; 50% of BCCs from the head/neck contained an aggressive histological subtype, compared with only 10% from other sites; four out of 139 papers found regarding surgical management of BCCs were from primary care practice.
  • DISCUSSION: Significant differences exist between the location mix and histological types of BCCs treated in general practice with those reported in the research literature.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / pathology. Family Practice / statistics & numerical data. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820836.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


Advertisement
4. Paavilainen V, Tuominen J, Aho VV, Saari KM: Long-term results after treatment of basal cell carcinoma of the eyelid in South-Western Finland. Eur J Ophthalmol; 2007 Jul-Aug;17:494-500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results after treatment of basal cell carcinoma of the eyelid in South-Western Finland.
  • : . PURPOSE: Basal cell carcinoma (BCC) is the most common skin cancer of the eyelid, showing an increasing incidence in the white population.
  • The authors studied the clinical characteristics and the treatment results of BCC of the eyelid in southwestern Finland during 1977-1997.
  • METHODS: The authors reviewed the case records of 191 patients with BCC of the eyelids treated at the Turku University Eye Clinic during 1977-1997.
  • RESULTS: The 191 patients had altogether 194 BCC tumors of the eyelid with the mean diameter of the tumor being smaller than 10 mm in 77.3% of cases.
  • Of the 194 BCC tumors of the eyelid 16.0% showed recurrence, and the recurrence rate of all surgically treated tumors was 13.7%.
  • In this study 61 patients (31.9%) developed other malignancies than the BCC of the eyelid including 28 patients (14.7 %) with carcinoma in other locations than skin.
  • CONCLUSIONS: Incompletely removed BCCs of the eyelid showed only 18.9% recurrence rate during the follow-up time.
  • On the other hand, BCCs of the eyelid should not be underestimated because of the rather high total recurrence rate.
  • The frequency of 31.9% of other malignancies than BCC of the eyelid is remarkably high and requires special attention from the ophthalmologist taking care of the patient with BCC of the eyelid.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28221540.001).
  • [ISSN] 1724-6016
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


5. Arad S, Zattra E, Hebert J, Epstein EH Jr, Goukassian DA, Gilchrest BA: Topical thymidine dinucleotide treatment reduces development of ultraviolet-induced basal cell carcinoma in Ptch-1+/- mice. Am J Pathol; 2008 May;172(5):1248-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical thymidine dinucleotide treatment reduces development of ultraviolet-induced basal cell carcinoma in Ptch-1+/- mice.
  • Treatment with thymidine dinucleotide (pTT) has well documented DNA-protective effects and reduces development of squamous cell carcinoma in UV-irradiated mice.
  • The preventive effect of pTT on basal cell carcinoma (BCC) was evaluated in UV-irradiated Ptch-1(+/-) mice, a model of the human disease Gorlin syndrome.
  • Topical pTT treatment significantly reduced the number and size (P < 0.001) of BCCs in murine skin after 7 months of chronic irradiation.
  • Skin biopsies collected 24 hours after the final UV exposure showed that pTT reduced the number of nuclei positive for cyclobutane pyrimidine dimers by 40% (P < 0.0002) and for 8-hydroxy-2'-deoxyguanosine by 61% (P < 0.01 compared with vehicle control).
  • Immunostaining with an antibody specific for mutated p53 revealed 63% fewer positive patches in BCCs of pTT-treated mice compared with controls (P < 0.01), and the number of Ki-67-positive cells was decreased by 56% (P < 0.01) in pTT-treated tumor-free epidermis and by 76% (P < 0.001) in BCC tumor nests (P < 0.001).
  • Terminal dUTP nick-end labeling staining revealed a 213% increase (P < 0.04) in the number of apoptotic cells in BCCs of pTT-treated mice.
  • We conclude that topical pTT treatment during a prolonged period of intermittent UV exposure decreases the number and size of UV-induced BCCs through several anti-cancer mechanisms.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2001 Feb 2;280(4):1042-7 [11162632.001]
  • [Cites] J Am Acad Dermatol. 2001 Feb;44(2):293-7 [11174390.001]
  • [Cites] EMBO J. 2001 Oct 1;20(19):5532-40 [11574485.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):8-18 [11684447.001]
  • [Cites] FASEB J. 2002 May;16(7):754-6 [11923222.001]
  • [Cites] Photochem Photobiol. 2002 Jul;76(1):73-80 [12126310.001]
  • [Cites] Australas J Dermatol. 2002 Nov;43(4):241-6 [12423429.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):527-31 [12515865.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):934-41 [14871823.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3933-8 [14999099.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4385-9 [15231643.001]
  • [Cites] FASEB J. 2004 Sep;18(12):1373-81 [15333580.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7545-52 [15492281.001]
  • [Cites] Medicine (Baltimore). 1987 Mar;66(2):98-113 [3547011.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10124-8 [1946433.001]
  • [Cites] Nature. 1992 Jul 2;358(6381):15-6 [1614522.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Feb 15;90(4):1614-8 [8434025.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4756-9 [8062275.001]
  • [Cites] Nature. 1994 Dec 1;372(6505):413-4 [7984233.001]
  • [Cites] Science. 1994 Dec 23;266(5193):1954-6 [7801120.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):274-8 [8552621.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1087-92 [8577719.001]
  • [Cites] J Natl Cancer Inst. 1996 Mar 20;88(6):349-54 [8609643.001]
  • [Cites] J Invest Dermatol. 1996 Nov;107(5):733-7 [8875958.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12627-32 [9356500.001]
  • [Cites] Nat Med. 1998 May;4(5):619-22 [9585239.001]
  • [Cites] J Invest Dermatol. 1999 Jan;112(1):25-31 [9886259.001]
  • [Cites] Science. 1999 Feb 26;283(5406):1321-5 [10037601.001]
  • [Cites] J Biol Chem. 1999 Apr 16;274(16):10911-5 [10196169.001]
  • [Cites] Cell. 1999 May 14;97(4):503-14 [10338214.001]
  • [Cites] Carcinogenesis. 1999 Oct;20(10):1939-44 [10506108.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2006-11 [15598755.001]
  • [Cites] Br J Dermatol. 2005 Jan;152(1):43-51 [15656799.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2005 Mar;19(2):180-6 [15752287.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6006-10 [16024598.001]
  • [Cites] J Biol Chem. 2005 Sep 16;280(37):32379-88 [16046401.001]
  • [Cites] J Investig Dermatol Symp Proc. 2005 Nov;10(2):124-30 [16363064.001]
  • [Cites] J Invest Dermatol. 2006 May;126(5):1143-51 [16528365.001]
  • [Cites] Prog Biophys Mol Biol. 2006 Sep;92(1):92-6 [16616325.001]
  • [Cites] FASEB J. 2006 Sep;20(11):1895-7 [16877521.001]
  • [Cites] J Cell Physiol. 2007 Mar;210(3):582-95 [17133364.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]
  • [Cites] J Invest Dermatol. 2000 Sep;115(3):435-40 [10951280.001]
  • [Cites] DNA Repair (Amst). 2007 Apr 1;6(4):544-59 [17112792.001]
  • [Cites] Breast Cancer Res. 2007;9(1):R13 [17257427.001]
  • [Cites] FASEB J. 2007 Sep;21(11):2918-30 [17449721.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Nov 1;224(3):257-64 [17276471.001]
  • [Cites] Science. 1997 Aug 22;277(5329):1109-13 [9262482.001]
  • (PMID = 18403589.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 10515; United States / NCI NIH HHS / CA / R01 CA109584; United States / NIAMS NIH HHS / AR / AR 050440; United States / NIAMS NIH HHS / AR / P01 AR050440; United States / NCI NIH HHS / CA / CA 109584
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Pyrimidine Dimers; 0 / Receptors, Cell Surface; 0 / Thymine Nucleotides; 0 / patched receptors; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; G9481N71RO / Deoxyguanosine
  • [Other-IDs] NLM/ PMC2329834
  •  go-up   go-down


6. Welchering T, Bernards M: [Basalioma-like skin tumor three years ago. Now new nodes appear almost daily]. MMW Fortschr Med; 2009 Oct 1;151(40):5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basalioma-like skin tumor three years ago. Now new nodes appear almost daily].
  • [MeSH-major] Carcinoma, Merkel Cell. Skin Neoplasms
  • [MeSH-minor] Aged. Humans. Male. Skin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] MMW Fortschr Med. 2010 Mar 25;152(12):18 [20394163.001]
  • (PMID = 19927906.001).
  • [ISSN] 1438-3276
  • [Journal-full-title] MMW Fortschritte der Medizin
  • [ISO-abbreviation] MMW Fortschr Med
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


7. Scherer D, Bermejo JL, Rudnai P, Gurzau E, Koppova K, Hemminki K, Kumar R: MC1R variants associated susceptibility to basal cell carcinoma of skin: interaction with host factors and XRCC3 polymorphism. Int J Cancer; 2008 Apr 15;122(8):1787-93
Hazardous Substances Data Bank. (L)-ARGININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MC1R variants associated susceptibility to basal cell carcinoma of skin: interaction with host factors and XRCC3 polymorphism.
  • The variants within the human melanocortin 1 receptor (MC1R) gene are associated with an increased risk of different skin cancers.
  • In this study, we genotyped by direct sequencing, 529 cases of basal cell carcinoma of the skin (BCC) and 533 healthy controls for polymorphisms in the entire MC1R gene.
  • The risk of BCC in the carriers of MC1R variants with fair complexion was almost twice as much as in the corresponding noncarriers.
  • The carriers of the R163Q variant with a medium skin complexion were at a 3-fold higher risk than the noncarrier counterparts.
  • The interaction, of effect on the BCC risk, between the MC1R variants and types of skin response to sun exposure was greater than multiplicative.
  • Our data confirmed the status of the nonsynonymous MC1R variants as independent genetic risk factors for BCC.
  • However, the mechanism through which the variants influence the risk likely involves complex interactions with other genetic and host risk factors.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. DNA-Binding Proteins / genetics. Polymorphism, Genetic. Receptor, Melanocortin, Type 1 / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Arginine. Case-Control Studies. Female. Genetic Predisposition to Disease. Genotype. Glutamine. Humans. Hungary. Male. Methionine. Middle Aged. Risk Factors. Romania. Sequence Analysis, DNA. Slovakia. Threonine

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Glutamine .
  • Hazardous Substances Data Bank. (L)-Methionine .
  • Hazardous Substances Data Bank. L-Threonine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067130.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Receptor, Melanocortin, Type 1; 0 / X-ray repair cross complementing protein 3; 0RH81L854J / Glutamine; 2ZD004190S / Threonine; 94ZLA3W45F / Arginine; AE28F7PNPL / Methionine
  •  go-up   go-down


8. Pinto Pereira SM, Hipwell JH, McCormack VA, Tanner C, Moss SM, Wilkinson LS, Khoo LAL, Pagliari C, Skippage PL, Kliger CJ, Hawkes DJ, Dos Santos Silva IM: Automated registration of diagnostic to prediagnostic x-ray mammograms: Evaluation and comparison to radiologists' accuracy. Med Phys; 2010 Sep;37(9):4530-4539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: X-ray mammograms were simulated from MRIs of 20 women using finite element methods for modeling breast compressions and employing a MRI/x-ray appearance change model.
  • Five mammography film readers independently identified landmarks (tumor, nipple, and usually two other normal features) on pairs of diagnostic and corresponding prediagnostic digitized images from 52 breast cancer cases.
  • Registration accuracy was sensitive to the type of landmark and the amount of breast density.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28524565.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Digital mammography / Film mammography / Finite element calculations / Image analysis / MRI / Magnetic resonance imaging / Mammography / Medical X-ray imaging / Medical imaging / Radiography / Registration / Tissues / X-ray imaging / affine transforms / biological organs / biomedical MRI / breast cancer / cancer / diagnostic radiography / finite element analysis / image registration / mammographic density / mammography / medical image processing / registration algorithms / tumours
  •  go-up   go-down


9. Moskalik KG, Kozlov AP, Boĭko EV, Ian AV, Novikov SA, Dubaĭsi I: [Potential of different kinds of laser irradiation in treatment of benign and malignant tumors of facial skin]. Vopr Onkol; 2005;51(1):113-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Potential of different kinds of laser irradiation in treatment of benign and malignant tumors of facial skin].
  • The use of neodymium, holmium and diode lasers proved highly-effective in the treatment of facial skin cancers stage I-II (3,051)( basalioma--2,804, recurrent basalioma--165, squamous cell tumor--82) and benign tumors (2,157).
  • Relapsed basaliomas after treatment from Pulsar-1,000 Ladoga- neodymium were reported in 1.6 and 3%, respectively.
  • When pulsed neodymium lasers were used, repeat relapsed basalioma and recurrences of squamous cell cancer were detected in 4.2 and 4.9%, respectively.
  • Since the radiation penetration capacity of neodymium lasers is relatively high, their application is preferable in treatment of facial skin cancer stage I-II as well as exophytic or in-depth benign tumors.
  • Holmium and diode lasers are better suited for destruction of superficial benign tumors.
  • [MeSH-major] Lasers. Skin Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15909819.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


10. Tot T: Eccrine ductal and acrosyringeal differentiation of the breast epithelium--a lesion associated with some metaplastic breast carcinomas. Virchows Arch; 2006 Nov;449(5):565-71
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eccrine ductal and acrosyringeal differentiation of the breast epithelium--a lesion associated with some metaplastic breast carcinomas.
  • Two cases of metaplastic breast carcinoma associated with eccrine ductal metaplasia in the surrounding breast tissue are reported.
  • In addition, in one of the cases, basalioma-like intraductal cell proliferation was observed, also showing focal acrosyringeal differentiation.
  • The invasive carcinomas, one of them representing "syringomatous squamous tumor of the breast" while the other diagnosed as high-grade metaplastic carcinoma, also showed focal eccrine and acrosyringeal differentiation and intensive diffuse maspin expression.
  • These previously unrecognized metaplastic changes of the breast epithelium may represent precursor lesions of certain types of metaplastic breast carcinomas.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Eccrine Glands / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17016720.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Keratin-5
  •  go-up   go-down


11. Mellert F, Schiller W, Yueruektuemen A, Preusse CJ, Welz A: A rare case of skin cancer above a subcutaneously implanted pacemaker: implications for future implants. Heart Surg Forum; 2008;11(3):E132-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of skin cancer above a subcutaneously implanted pacemaker: implications for future implants.
  • BACKGROUND: The occurrence of a skin neoplasm close to the position of an implanted pacemaker or cardioverter-defibrillator device is not very common.
  • CASE REPORT: We report on an 82-year-old patient who developed a basal cell carcinoma in the skin directly above a subcutaneously implanted pacemaker generator.
  • The patient presented with a history of recurrent basalioma at various locations.
  • CONCLUSION: Primary submuscular implantation of pacemaker devices should be carefully considered in elderly patients with a history of previous skin tumors.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / surgery. Device Removal. Pacemaker, Artificial / adverse effects. Skin Neoplasms / etiology. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pacemakers and Implantable Defibrillators.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18583279.001).
  • [ISSN] 1522-6662
  • [Journal-full-title] The heart surgery forum
  • [ISO-abbreviation] Heart Surg Forum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Seili-Bekafigo I, Jonjić N, Stemberger C, Rajković-Molek K: Additional cytomorphological criteria in diagnosis of pilomatricoma--benign tumor with bad reputation. Coll Antropol; 2010 Mar;34(1):117-22
Hazardous Substances Data Bank. METHYLENE BLUE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Additional cytomorphological criteria in diagnosis of pilomatricoma--benign tumor with bad reputation.
  • Pilomatricomas (PM) are benign skin appendageal tumors, with differentiation towards hair-forming cells, usually found in children.
  • PM are often mistaken for "small round blue cell" tumors in children, or for Merkel cell carcinoma, basalioma and metastatic small cell carcinoma in adults, with possible over-aggressive therapeutic approach.
  • We present 6 cases of PM, correctly diagnosed preoperatively by FNA.
  • Clinical, cytomorphologic and basic morphometric features were analyzed, and compared with 4 cases of malignant tumors with similar clinical presentation.
  • Morphometric data (longest nuclear diameter) did not prove to be helpful, while basophilic cytoplasmatic protrusions, observed in all 6 analyzed cases, could be useful additional cytomorphologic feature of PM.
  • We concluded that cytomorphologic characteristics of PM are reliable enough for correct preoperative diagnosis in adequate specimens, however the best results are achieved when FNA is performed by an experienced cytologist, and when all relevant clinical data are obtained.
  • [MeSH-major] Carcinoma, Skin Appendage / pathology. Neoplasms / pathology. Pilomatrixoma / pathology. Sarcoma, Ewing / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Carcinoma, Basal Cell / pathology. Carcinoma, Merkel Cell / pathology. Child. Diagnosis, Differential. Eosine Yellowish-(YS). Epithelial Cells / pathology. Female. Humans. Male. Methylene Blue. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432739.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / May-Grunwald Giemsa; T42P99266K / Methylene Blue; TDQ283MPCW / Eosine Yellowish-(YS)
  •  go-up   go-down


13. Martinsson H, Yhr M, Enerbäck C: Expression patterns of S100A7 (psoriasin) and S100A9 (calgranulin-B) in keratinocyte differentiation. Exp Dermatol; 2005 Mar;14(3):161-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • S100A7 and S100A9 have been shown to be markedly upregulated both in ductal carcinoma in situ of the breast and in psoriasis.
  • They were both absent in undifferentiated basalioma and strongly expressed in carcinoma in situ, as well as in keratoacanthoma and differentiated squamous cell carcinoma.
  • In normal epithelium, they were expressed in the superficial, differentiated region of the epithelium rather than in the basal region.
  • [MeSH-minor] Blotting, Western. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Differentiation / physiology. Cell Line. Computer Systems. Humans. Immunohistochemistry. Keratoacanthoma / metabolism. Keratoacanthoma / pathology. Polymerase Chain Reaction. Reverse Transcriptase Polymerase Chain Reaction. S100 Proteins. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15740587.001).
  • [ISSN] 0906-6705
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Calgranulin B; 0 / S100 Proteins; 0 / S100A7 protein, human
  •  go-up   go-down


14. Ott C, Huber S: [The clinical significance of cosmic radiation in aviation]. Praxis (Bern 1994); 2006 Jan 25;95(4):99-106
MedlinePlus Health Information. consumer health - Occupational Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Seven out of nine studies found an identical or decreased over-all-risk for aviators to develop cancer of any kind compared to the general population.
  • In re- gards to skin cancer, seven out of eight studies found an increased risk for aviators to develop malignant melanoma, basalioma or other kinds of skin cancer.
  • Three studies found an increased risk for the development of prostate cancer and two studies were able to demonstrate a higher risk for the appearance of leukaemia.
  • CONCLUSIONS: Although our review found some studies, that identified higher risks for pilots to develop cancer of the skin, prostate cancer or leukaemia, there is not enough scientific evidence to support the hypothesis, that cosmic radiation is the cause for these findings.
  • [MeSH-minor] Aerospace Medicine. Carcinoma, Basal Cell / epidemiology. Cohort Studies. Confidence Intervals. Humans. Leukemia, Radiation-Induced / epidemiology. Male. Melanoma / epidemiology. Occupational Exposure / adverse effects. Prospective Studies. Prostatic Neoplasms / epidemiology. Retrospective Studies. Risk Factors. Skin Neoplasms / epidemiology. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485604.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 21
  •  go-up   go-down


15. Buljan M, Bulat V, Situm M, Mihić LL, Stanić-Duktaj S: Variations in clinical presentation of basal cell carcinoma. Acta Clin Croat; 2008 Mar;47(1):25-30
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variations in clinical presentation of basal cell carcinoma.
  • Basal cell carcinoma (basalioma, BCC) is the most common skin cancer and the most common human malignancy in general, with a continuously increasing incidence.
  • In most cases, BCC develops on chronically sun-exposed skin in elderly people, most commonly in the head and neck region.
  • Besides chronic UV radiation, other risk factors for the development of BCC include sun bed use, family history of skin cancer, skin type 1 and 2, a tendency to freckle in childhood, immunosuppression, previous radiotherapy, and chronic exposure to certain toxic substances such as inorganic arsenic.
  • There are numerous variations in clinical presentation of BCC, such as nodular BCC, ulcerating BCC, pigmented BCC, sclerosing BCC, superficial BCC, and fibroepithelioma of Pinkus.
  • Treatment modalities for BCC include surgical excision, cryosurgery, curettage, electrodessication, radiotherapy, photodynamic therapy, topical cytostatics, and immunomodulators.
  • If left untreated or inadequately treated, BCC may become invasive and locally destructive, although it very rarely metastasizes.
  • Due to the extremely high incidence of BCC, medical professionals should be familiar with its manifold clinical presentations.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18714644.001).
  • [ISSN] 0353-9466
  • [Journal-full-title] Acta clinica Croatica
  • [ISO-abbreviation] Acta Clin Croat
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Croatia
  • [Number-of-references] 13
  •  go-up   go-down


16. Booth CM, Li G, Mackillop WJ: The impact of socioeconomic status (SES) on stage of cancer at time of diagnosis: A population-based study in Ontario, Canada. J Clin Oncol; 2009 May 20;27(15_suppl):6505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of socioeconomic status (SES) on stage of cancer at time of diagnosis: A population-based study in Ontario, Canada.
  • : 6505 Background: Lower SES is known to be associated with worsened cancer survival.
  • Here we evaluate the impact of SES on stage of cancer at diagnosis in Ontario which has universal health insurance.
  • METHODS: All incident cases of breast, colon, rectal, non-small cell lung, cervical and larynx cancer diagnosed in Ontario 2003-2005 were identified using the Ontario Cancer Registry.
  • Stage information is only captured routinely for patients seen at Ontario's 8 Regional Cancer Centers (RCCs).
  • Using a best stage grouping approach, cases were assigned stage based on pathologic TNM if available and clinical TNM otherwise.
  • Using postal code at time of diagnosis cases were assigned to quintiles (Q); Q1 represents the communities where the poorest 20% of the Ontario population resided.
  • RESULTS: Stage at diagnosis was available for 19,239/23,254 (83%) of cases seen at RCCs.
  • Among cases with breast cancer, those in Q1 were less likely to have stage I disease (43 vs 47%, p = 0.004) and more likely to have stage IV disease (5 vs 4%, 0.008) than Q2-5.
  • With lung cancer, cases in Q1 were more likely to have stage I disease compared to Q2-5 (16 vs 13%, p = 0.015).
  • Distribution of stage I and stage IV disease did not differ by SES across other individual diseases.
  • However, for all 6 cancers combined, cases in Q1 were less likely than Q2-5 to have stage I disease (27 vs 30%, p = 0.001) and more likely to have stage IV disease (21 vs 18%, p < 0.0001).
  • We found significant gradients in 3-year overall survival across Q1-Q5 for breast (5% absolute difference in survival, p < 0.001), colon (4%, p = 0.049), and cervical (18%, p = 0.031) cancers.
  • CONCLUSIONS: Despite universal health care, SES remains associated with survival among patients with cancer in Ontario.
  • These data suggest that the difference in outcome is only partially explained by differences in stage at diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964005.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Maiti B, Kundranda MN, Jin T, Spiro TP, Daw HA: The association of metabolic syndrome with triple-negative breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):1038

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association of metabolic syndrome with triple-negative breast cancer.
  • : 1038 Background: Metabolic syndrome, a conglomerate of obesity, insulin resistance, hypertriglyceridemia, low HDL (high density lipoprotein), and hypertension is associated with an increased risk of breast cancer.
  • However, no clear association has been shown between the highly aggressive triple-negative breast cancer and metabolic syndrome.
  • METHODS: In a retrospective review we compared triple-negative and non-triple-negative breast cancer cases for the presence of metabolic syndrome by NCEP (National Cholesterol Education Program) or AACE (American Association of Clinical Endocrinologists) definitions.
  • Data on metabolic syndrome criteria, tumor size, grade, lymph node status, and ductal carcinoma in situ (DCIS) were reviewed.
  • RESULTS: The entire cohort of 176 patients (12.5% African-American) with median age 56.5 years (range 26-91 years) comprised of 86 triple-negative cases and 90 non-triple-negative cases.
  • A statistically significant association of triple-negative breast cancer with metabolic syndrome was observed.
  • Contrary to blood glucose, triglyceride, or HDL levels, which independently showed significant association with triple-negative breast cancer, hypertension, or BMI showed no independent association.
  • Additionally, triple-negative tumors displayed a significantly higher histologic grade and relative paucity of ductal carcinoma in situ (DCIS) when compared to the non-triple negative tumors (p < 0.001).
  • CONCLUSIONS: The data suggests that the metabolic syndrome is significantly more prevalent in triple-negative breast cancer patients when compared to the non-triple-negative patients.
  • Additionally, triple-negative breast cancer showed a significantly higher histologic grade and a relative absence of DCIS.
  • Whether the presence of metabolic syndrome preferentially increases the risk of developing triple-negative-breast cancer needs to be elucidated by future prospective studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961078.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Visram H, Dent SF: Toxicities and adherence rates of hormone treatment in male breast cancer patients treated at a tertiary care center. J Clin Oncol; 2009 May 20;27(15_suppl):e11613

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicities and adherence rates of hormone treatment in male breast cancer patients treated at a tertiary care center.
  • : e11613 Background: Male breast cancer (BC) comprises approximately 1% of all breast cancer cases, and over 80% of male BC tumours express the estrogen receptor (ER).
  • METHODS: We conducted a retrospective chart review of 24 pts diagnosed with male BC at the Ottawa Regional Cancer Centre from 1986-2003.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961143.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Blázquez-Sánchez N, de Troya-Martín M, Frieyro-Elicegui M, Fúnez-Liébana R, Martín-Márquez L, Rivas-Ruiz F: Cost Analysis of Mohs Micrographic Surgery in High-Risk Facial Basal Cell Carcinoma. Actas Dermosifiliogr; 2010 Sep;101(7):622-628

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost Analysis of Mohs Micrographic Surgery in High-Risk Facial Basal Cell Carcinoma.
  • [Transliterated title] Análisis de costes de la cirugía micrográfica de Mohs en el carcinoma basocelular facial de alto riesgo.
  • INTRODUCTION: Mohs micrographic surgery (MMS) is the treatment of choice for high-risk facial basal cell carcinoma (BCC) as it offers the greatest chance of cure with maximum preservation of healthy tissue.
  • OBJECTIVES: To determine the cost of MMS with fresh tissue to treat high-risk facial BCC and compare this to the estimated cost of conventional surgery in a Spanish public hospital.
  • MATERIAL AND METHODS: Cross-sectional study of a consecutive series of patients with high-risk facial BCC who underwent MMS at the Department of Dermatology at Hospital Costa del Sol in Malaga, Spain between July 2006 and December 2007.
  • RESULTS: Seventy-nine patients (mean age, 62 years) with 81 high-risk facial BCCs, 97.5% of which were primary tumors, underwent MMS.
  • Histology showed that 64% of the tumors were infiltrative or micronodular carcinomas.
  • Tumor-free margins were achieved in all patients, with no more than 2 stages required in 88% of the cases.
  • The most common surgical reconstruction techniques were direct closure (21%) and closure with a local skin flap or graft (71%); the corresponding estimates for conventional surgery were 2% and 89%, respectively.
  • CONCLUSIONS: MMS is a viable, effective technique that does not generate significantly higher costs than conventional surgery in selected patients with high-risk facial BCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier España, S.L. y AEDV. All rights reserved.
  • (PMID = 28709544.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliograficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Keywords] NOTNLM ; Análisis de costes / Cirugía micrográfica / Cost analysis / Cost-effectiveness / Coste/beneficio / Micrographic surgery / Mohs
  •  go-up   go-down


20. Svetlosáková Z, Halás M, Krásnik V, Strmen P: [Basalioma of the eyelid: rate and factors of recurrence after surgical therapy]. Cesk Slov Oftalmol; 2010 Oct;66(4):171-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basalioma of the eyelid: rate and factors of recurrence after surgical therapy].
  • The aim of our study was to evaluate a recurrence rate of basalioma of the eyelid after surgical therapy.
  • MATERIAL AND METHODS: Retrospective analysis of data from patients with basalioma of the eyelid treated surgically at the Department of Ophthalmology, Faculty of Medicine Comenius University in Bratislava during the years 2005-2007.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21394970.001).
  • [ISSN] 1211-9059
  • [Journal-full-title] Ceská a slovenská oftalmologie : casopis Ceské oftalmologické spolecnosti a Slovenské oftalmologické spolecnosti
  • [ISO-abbreviation] Cesk Slov Oftalmol
  • [Language] slo
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


21. Elabjer BK, Petrinović-Doresić J, Busić M, Elabjer E, Kastelan S: Retrospective analysis of reconstruction techniques after periocular basalioma excision. Coll Antropol; 2007 Jan;31 Suppl 1:91-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of reconstruction techniques after periocular basalioma excision.
  • The paper presents our approach to reconstruction after periocular basalioma (pBCC) excision, especially of large lower lid (LL) and medial canthal (MC) pBCC.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Surgical Flaps

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17469760.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


22. Shapiro G, Kwak E, Baselga J, Rodon J, Scheffold C, Laird AD, Bedell C, Edelman G: Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In preclinical cancer models XL147 is cytostatic or cytoreductive as monotherapy and enhances the efficacy of targeted agents and chemotherapeutics.
  • Drug-related toxicities included grade 3 skin rash (3 pts), grade 3 arterial thrombosis (1 pt), grade 2 transaminase elevation (1 pt), and grade 1 hyperglycemia (4 pts).
  • XL147 reached steady-state plasma concentrations by Day 15-20.
  • XL147 reduced levels of phosphorylated PI3K pathway components in PBMCs, hair, skin, and tumor tissues in an exposure-dependent manner.
  • As of December 2008, 6 pts (3 NSCLC, 1 BCC, 1 NHL, 1 PC) continued on study >6 months including 3 >10 months (NHL, NSCLC, BCC).
  • The most common drug-related toxicity was skin rash.
  • Prolonged stable disease has been observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961287.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Hao X, Liu Y, Hui R, Zhang J: Comparison of the sensitivity to endocrine therapy of PR+/ER- patients and ER+/PR- patients with HER2+ breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11558

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the sensitivity to endocrine therapy of PR+/ER- patients and ER+/PR- patients with HER2+ breast cancer.
  • : e11558 Background: Her2 and PR expression are important indicators for prognosis of breast cancer.
  • METHODS: Collected 3,677 primary breast cancer cases from 2002 to 2004 in Tianjin University Cancer Hospital.
  • All of the cases were confirmed by pathohistological method.
  • With Her2+ breast cancer, 168 patients are PR+/ER- and 211 patients are ER+/PR-.
  • With Her2+ BC, 3-year DFS(disease-free survival rate) of PR+/ER- patients is 94.53%, higher than that of PR-/ER+ ones (91.81%).With Her2- BC, 3-year DFS of PR+/ER- patients is lower than that of PR-/ER+ (p<0.05).
  • 3. Total of 1853 cases with 5-year followed up, and 1297 cases have been given endocrine therapy.
  • CONCLUSIONS: With Her2+ breast cancer, 3-year DFS of PR+/ER- patients is higher than ER+/PR- and also PR+/ER- patients may more sensitive to endocrine therapy than ER+/PR- patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964105.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Wafa T: Contribution of BRCA1 and BRCA2 mutations to breast cancer in Tunisia. J Clin Oncol; 2009 May 20;27(15_suppl):e22191

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contribution of BRCA1 and BRCA2 mutations to breast cancer in Tunisia.
  • : e22191 Background: Hereditary breast cancer accounts for 3-8% of all breast cancers.
  • It was recently estimated that a combination of BRCA1 and BRCA2 genes mutations is responsible for 30% of hereditary breast cancer cases.
  • METHODS: To investigate the prevalence of BRCA1 and BRCA2 gene mutations in breast cancer patients with affected relatives in Tunisia, 36 patients who had at least one first degree relative affected with breast and/or ovarian cancer were analysed.
  • Nineteen percent (7/36) of the familial cases were altered on BRCA1 or BRCA2 genes with deleterious mutations at heterozygous state and 55% (20/36) by mutation with uncertain value (UV) or by single nucleotide polymorphisms (SNPs).
  • CONCLUSIONS: Almost all the cases mutated by deleterious mutations on BRCA1 gene reported a family history of breast and/or ovarian cancer in the index case or in their relatives.
  • On the contrary, patients with an UV mutation or SNPs have no history of ovarian cancer in their corresponding families.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963625.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Wang X, Li Y, Cao X: False-positive diagnosis of breast cancer by diffused optical tomography with ultrasound. J Clin Oncol; 2009 May 20;27(15_suppl):e22085

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] False-positive diagnosis of breast cancer by diffused optical tomography with ultrasound.
  • : e22085 Background: Breast cancer is one of the most common cancer in women.
  • Early detection, early diagnosis and early treatment play key role in fighting against breast cancer.
  • It provides dual modality images for early diagnosis of breast cancer.
  • The aim of this study was to evaluate the OPTIMUS system on diagnosis of breast disease.
  • METHODS: OPTIMUS system was applied to 160 breast tumor patients.
  • All patients had received surgical treatment and had definite pathological diagnosis.
  • OPTIMUS system was evaluated as diagnostic tool of breast tumor in this study.
  • RESULTS: There were 42 cases diagnosed as benign breast disease and 118 cases diagnosed as breast cancer by OPTIMUS system.
  • Pathology confirmed 60 cases of benign disease and 100 cases of breast cancer.
  • False positive rate of breast cancer was 30% (18/60).
  • False negative rate of breast cancer was 0% (0/100).
  • The pathology of false positive cases was mild and severe papillomatosis (6/18), non-typical hyperplasia (4/18), chronic inflammation (3/18), fibroadenoma (3/18) and fat necrosis (2/18).
  • Papillomatosis and non-typical hyperplasia are precancerous lesions and often difficult for clinical diagnosis.
  • CONCLUSIONS: OPTIMUS system is a non- invasive and highly effective diagnostic tool for breast disease.
  • Its sensitivity is reached to 100% and specificity is about 70% on the diagnosis of breast cancer.
  • OPTIMUS system could be used as assistant diagnostic tool for breast tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963263.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Gercovich N, Gil Deza E, Russo M, Garcia Gerardi C, Diaz C, Morgenfeld E, Rolnik B, Emina J, Rivarola E, Gercovich FG: Early-stage male breast cancer: A 10-year experience. J Clin Oncol; 2009 May 20;27(15_suppl):e11630

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-stage male breast cancer: A 10-year experience.
  • : e11630 Introduction: Male breast cancer is very rare, representing only between 0.7% and 1% of all breast cancers, and only half of them are early stage cases.
  • OBJECTIVE: The present study has been designed with the aim of studying retrospectively the clinical onset and evolution of male invasive breast cancer patients (stages I and II) treated at IOHM between 1997 and 2008.
  • METHODS: The records of 3,000 breast cancer cases followed between 1997 and 2008 were searched, looking for male stage I and II breast cancer patients.
  • Tumoral type= Invasive Ductal Carcinoma 12 pt.
  • Tumoral subtype= NOS 9 pt (75%) Apocrine 2 pt (17%) Micropapillar 1 pt (8%).
  • Twelve stage I and II male breast cancer patients were identified out of 3000 (0.4%) breast cancer cases diagnosed and followed in the past 10 years at the IOHM.
  • 2. Mastectomy was the surgical procedure in 11 of the 12 cases 3.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961181.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Fury MG, Sherman E, Stambuk H, Haque S, Lisa D, Shen R, Carlson D, Pfister DG: Phase I study of everolimus (E; RAD001) + low-dose weekly cisplatin (C) for patients with advanced solid tumors: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):e14527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients received E per oral for days 1-21 of a 28 day cycle.
  • At DL1, 3 patients were inevaluable (1 withdrawal of consent prior to treatment, 1 disease progression during cycle 1, 1 recurrent diverticulitis during cycle 1) and were replaced.
  • Minor response seen in pulmonary carcinoid (n = 1); prolonged SD ≥ 6 cycles seen in pulmonary carcinoid (n=2), basal cell carcinoma (n=1), and esthesioneuroblastoma (n=1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963576.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Kozyreva ON, Konnikov N: The incidence of non-melanoma skin cancer after a single field treatment with aminolevulinic acid and blue light photodynamic therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e14646

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of non-melanoma skin cancer after a single field treatment with aminolevulinic acid and blue light photodynamic therapy.
  • : e14646 Background: Non-melanoma skin cancer (NMSC) is the most common form of human cancer.
  • RESULTS: 43 Caucasian males (range 59- 87 yrs), 37 (87%) had history of NMSC on the face or scalp, 32 (78%) had basal cell carcinoma (BCC), 11 (22%) squamous cell carcinoma (SCC), 100% of patients had multiple (>4) AKs prior to treatment and 23 (75% ) had moderate to severe DH determined by Griffiths scale.
  • Prior to ALA-PDT 74 NMSC's were documented: 40 (54%) BCC and 34 (46%) SCC.
  • 46 NMSC's were documented following ALA-PDT: 22 (48%) BCC and 24 (52%) SCC.
  • Prior to ALA-PDT, the frequency of BCC averaged 2 [IQR 1 to 3, max=4], and the frequency of SCC averaged 1 [IQR 1 to 1, max=3].
  • Following ALA-PDT, the occurrence of BCC averaged 1 [IQR 0 to 1, max=5], and that of SCC averaged 1 [IQR 0 to 2, max= 4].
  • The difference between BCC frequency before and after ALA-PDT treatment shown a significant reduction in BCC incidence (P = 0.0018).
  • No such differences were observed between the frequency of SCC before and after ALA-PDT (P=0.6230) Conclusions: A single ALA-PDT treatment to the face or scalp in high risk patients significantly reduces the incidence of BCC, the incidence of SCC was not reduced.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964235.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Jirakulaporn T, Mathew J, Lindgren BR, Dudek AZ: Efficacy of capecitabine in secondary prevention of skin cancer in solid organ-transplanted recipients (OTR). J Clin Oncol; 2009 May 20;27(15_suppl):1519

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of capecitabine in secondary prevention of skin cancer in solid organ-transplanted recipients (OTR).
  • : 1519 Background: Skin cancers are the most common malignancies in OTR.
  • Topical 5% 5-FU has been used to successfully treat squamous cell carcinoma (SCC) in situ and actinic keratosis (AK).
  • Capecitabine, an orally-administered prodrug of 5-FU, in combination with interferon was shown to be effective in the treatment of advanced SCC of the skin.
  • This study was to determine the efficacy of low-dose capecitabine in secondary prevention of the skin cancers in OTR.
  • METHODS: OTR who developed recurrent skin cancers, SCC, and/or basal cell carcinoma (BCC), were given low-dose capecitabine 1g/m2 divided in two daily doses, day 1-14 of 21-day treatment cycle.
  • Skin surveillances were performed by dermatologists every 1 to 3 months.
  • Cumulative incidence rates of SCC, BCC, and AK before and after treatment were scored and statistically compared for each patient with a non-parametric Wilcoxon signed-rank test.
  • Mean incidence rates of SCC, BCC, and AK before treatment were 0.45, 0.05, and 4.99 lesions per month, respectively.
  • Mean incidence rates of SCC, BCC, and AK after treatment were 0.22, 0.04, and 2.80 lesions per month, respectively.
  • The differences in incidence rates of SCC, BCC, and AK before and after treatment were 0.24, 0.02, and 2.08 lesions per month with p value of 0.048, 0.844, and 0.151, respectively.
  • Age and the number of transplants were not significantly related to the change in incidence rates for all skin lesion types.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964327.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Arco G, Horch RE, Arkudas A, Dragu A, Bach AD, Kneser U: Double pedicled perforator flap to close flank defects: an alternative for closure of a large lumbar defect after basalioma excision--a case report and review of the literature. Ann Plast Surg; 2009 Oct;63(4):422-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double pedicled perforator flap to close flank defects: an alternative for closure of a large lumbar defect after basalioma excision--a case report and review of the literature.
  • Large defects following resection of skin cancers are sometimes a challenge for the reconstructive surgeon.
  • Although skin grafts are considered as the first choice for reconstruction of large skin defects at the trunk region, pedicled or free flaps provide sometimes a superior functional and aesthetic outcome.
  • The progress in understanding the perforator vessel system of the body facilitated the development of a plethora of novel pedicled flaps which could be transferred over long distances with minimal donor site morbidity.
  • We present a patient suffering from a large exulcerated basalioma at the lumbar region.
  • The skin defect after excision was reconstructed using a novel concept based on 2 independent pedicled perforator flaps, a lumbar artery perforator, and a lateral intercostal artery perforator.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Reconstructive Surgical Procedures / methods. Skin Neoplasms / surgery. Surgical Flaps / blood supply
  • [MeSH-minor] Follow-Up Studies. Graft Survival. Humans. Lumbosacral Region. Male. Middle Aged. Skin Transplantation / methods. Tissue Expansion / methods. Tissue and Organ Harvesting. Treatment Outcome. Wound Healing / physiology

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19745707.001).
  • [ISSN] 1536-3708
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


31. Situm M, Buljan M, Bulat V, Lugović Mihić L, Bolanca Z, Simić D: The role of UV radiation in the development of basal cell carcinoma. Coll Antropol; 2008 Oct;32 Suppl 2:167-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of UV radiation in the development of basal cell carcinoma.
  • Basal cell carcinoma (basalioma, BCC) is undoubtedly the most common malignant skin cancer and the most common human malignancy in general, with the continuous increase in its incidence.
  • BCC is generally a disorder of white individuals, especially those with fair skin.
  • UV radiation is the most important risk factor in the development of BCC.
  • Short-wavelength UVB radiation (290-320 nm, sunburn rays) is believed to play a greater role in BCC formation than long-wavelength UVA radiation (320-400 nm, tanning rays).
  • A latency period of 20-50 years is typical between the time of UV damage and the clinical onset of BCC.
  • Therefore, in most cases BCC develops on chronically sun-exposed skin in elderly people, most commonly in the area of head and neck.
  • UVB radiation damages DNA and its repair system and alters the immune system resulting in a progressive genetic alterations and formation of neoplasm.
  • UV-induced mutations in the TP53 tumor-suppressor gene have been found in about 50% of BCC cases.
  • Epidemiologic studies demonstrate the higher incidence of the BCC in more equatorial latitudes than in polar latitudes.
  • Other risk factors for the development of BCC include sun bed use, family history of skin cancers, skin type 1 and 2, immunosuppression, previous radiotherapy, and chronic exposure to toxic substances such as inorganic arsenic.
  • Although rarely metastatic, its malignant nature is sometimes emphasized by the local tissue destruction, disfigurement, and even death if left untreated.
  • Due to extremely high incidence of BCC medical professionals should be aware of the importance of the public education on the etiology of this tumor and the importance of the UV protection.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Skin Neoplasms / etiology. Ultraviolet Rays / adverse effects
  • [MeSH-minor] DNA Damage. Humans. Receptors, Cell Surface / radiation effects. Risk Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138022.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / patched receptors
  • [Number-of-references] 29
  •  go-up   go-down


32. Gorin MA, Iniesta MD, Douglas JA, Milliron KJ, Merajver SD: Absence of the CHEK2*1100delC mutation in non-BRCA1/2 families with multiple cancer types in a high-risk clinic population of Caucasian ancestry. J Clin Oncol; 2009 May 20;27(15_suppl):11040

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of the CHEK2*1100delC mutation in non-BRCA1/2 families with multiple cancer types in a high-risk clinic population of Caucasian ancestry.
  • : 11040 Background: Checkpoint kinase 2(CHEK2) is a cell-cycle-checkpoint kinase that phosphorylates p53 and BRCA1 in response to DNA damage.
  • The contribution of CHEK2 mutations to familial cancer has been widely studied in breast cancer.
  • Most notably, the CHEK2*1100delC mutation has been characterized to confer a 2-fold increased risk for breast cancer in carriers.
  • This finding comes from studies performed on Northern and Eastern European populations.
  • In contrast to the work done in Europe, these studies suggest a lower frequency of CHEK2*1100delC mutations in breast cancer families.
  • The aim of this study was to determine the frequency of CHEK2*1100delC in members of breast cancer families who tested negative for a deleterious mutation in BRCA1/2.
  • Families were characterized by the presence of several cases of breast and/or ovarian cancer and multiple members with other cancers in a single lineage.
  • RESULTS: No CHEK2*1100delC mutations were detected in 115 individuals, including 39 women diagnosed with breast cancer at an early age, 7 women with bilateral cancer, 2 men with breast cancer and 6 women with ovarian cancer, all of whom were negative for mutations in BRCA1/2.The CHEK2 Breast Cancer Consortium previously reported a frequency of 2.3% for the CHEK2*1100delC mutation among breast cancer cases from families with at least 2 cases of breast cancer (or breast and ovarian cancer) in a first- or second-degree relationship.
  • CONCLUSIONS: Our data are consistent with previous reports that suggest a lower frequency of CHEK2*1100delC mutations in North American hereditary breast cancer families without BRCA1/2 mutations and enriched for multiple cancer types.
  • The low frequency of the CHEK2*1100delC in the North American population limits its clinical relevance as a cancer predisposing gene.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963982.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Olsson H, Attner B, Noreen D, Lithman T: Comorbidity prior to diagnosis in patients with common cancer diagnoses. J Clin Oncol; 2009 May 20;27(15_suppl):e22180

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comorbidity prior to diagnosis in patients with common cancer diagnoses.
  • : e22180 Background: Chronic disease as diabetes, hypertonia and anemia may be associated with cancer risk as well as affect the short term survival of the malignancy.
  • METHODS: Using population based registry data from specialist and primary care in our health care region comorbidity in the form of anemia, hypertonia, diabetes, rheumatoid arthritis, chronic obstructive pulmonary diasease (KOL), and alcohol related diseases for patients with colon-, rectal-, lung-, prostate and breast cancer and survival were studied.
  • Altogether 2047 colon cancer cases, 985 rectal cancer cases, 2017 lung cancer cases, 3578 breast cancer cases and 5106 prostate cancer cases diagnosed 2000-2005 were included.
  • Comorbidity was studied prior to cancer diagnosis and in order to compare with the general population all first comorbidity diagnoses within 90 days were censored.
  • Patients with colon and rectal cancer had a higher prevalence of anemia, and diabetes.
  • Patients with lung cancer had a higher prevalence of anemia, KOL, diabetes, rheumatoid arthritis for both men and women and for men also a higher prevalence of alcohol related diseases.
  • Except for alcohol related diseases in females with breast cancer comorbidity for the above diseases was not significantly elevated for breast or prostate cancer.
  • Survival of the different cancer diagnoses was not significantly related to the comorbidity except for a tendency of worse survival for patients with alcohol related disease.
  • CONCLUSIONS: The prevalence of some common chronic diseases are elevated especially in colon-, rectal and lung cancer patients.
  • The comorbidity does not seem to affect short term survival of the cancer patient except for alcohol related diagnoses.
  • Our study also indicates the necessity to have all levels of care included in the study base of comorbidity and also emphasizes the need to censor time prior to diagnosis when comparing data with the general population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963595.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Iturbe J Jr, Zwenger A, Lacava JA, Perez Verdera P, Vallejo C, Romero A, Leone JP, Perez J, Maccihavelli M, Leone B: Treatment of early breast cancer (EBC): A long-term follow-up study-GOCS experience. J Clin Oncol; 2009 May 20;27(15_suppl):e11610

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of early breast cancer (EBC): A long-term follow-up study-GOCS experience.
  • : e11610 Background: Most cases of breast cancer are diagnosed at early stage of disease, therefore treatment is oriented to increase the relapse-free survival (RFS) and overall survival (OS).
  • RFS was analyzed from the date of initial diagnosis to the date of local or distant recurrence.
  • OS was estimated from the date of initial diagnosis to the last follow-up or date of death.
  • Adjuvant radiation therapy was administered to 73% of pts, whereas adjuvant chemotherapy to 29% and adjuvant hormone therapy to 18.5% of cases.
  • Local recurrence was documented in 37 pts (3.8%) whereas 269 developed metastatic disease (29%).
  • Bilateral breast cancer was seen in 102 cases (10.9%) and 91 pts (9.7%) developed 2nd malignancies.
  • This group of pts continues to have a good prognosis as shown by the OS rate at 5, 10, 15, 20 and 25 years, although high percentage of pts continue to have recurrence and die from breast cancer after 5, 10, 15, 20 and 25 years of follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961127.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Snarskaia ES, Suchkov SV, Molochkov VA: [Modern programs of treatment and rehabilitation of patients with basaliomas: their pathogenic substantiation and clinical effectiveness]. Vestn Ross Akad Med Nauk; 2005;(6):41-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Modern programs of treatment and rehabilitation of patients with basaliomas: their pathogenic substantiation and clinical effectiveness].
  • With the aim of forming modern programs for immunogenetic therapy of epithelial tumors, such as methatypic and basal cell carcinomas, the authors of the article analyze the basics of their immunopathogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16022112.001).
  • [ISSN] 0869-6047
  • [Journal-full-title] Vestnik Rossiiskoi akademii meditsinskikh nauk
  • [ISO-abbreviation] Vestn. Akad. Med. Nauk SSSR
  • [Language] RUS
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Cancer Vaccines; 0 / HLA-DR Antigens
  • [Number-of-references] 44
  •  go-up   go-down


36. Gufler H, Franke FE, Rau WS: High-resolution MRI of basal cell carcinomas of the face using a microscopy coil. AJR Am J Roentgenol; 2007 May;188(5):W480-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution MRI of basal cell carcinomas of the face using a microscopy coil.
  • OBJECTIVE: The objective of this article is to evaluate the diagnostic accuracy of high-resolution MRI using a microscopy surface coil to stage basal cell carcinomas of the face.
  • CONCLUSION: High-resolution MRI using a microscopy surface coil is a promising method to determine the extension of basaliomas of the facial region and to exclude infiltration of bone by the tumor.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Magnetic Resonance Imaging / methods. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17449748.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Vernez M, Hutter P, Monnerat C, Halkic N, Gugerli O, Bouzourene H: A case of Muir-Torre syndrome associated with mucinous hepatic cholangiocarcinoma and a novel germline mutation of the MSH2 gene. Fam Cancer; 2007;6(1):141-5
Hazardous Substances Data Bank. L-SERINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of Muir-Torre syndrome associated with mucinous hepatic cholangiocarcinoma and a novel germline mutation of the MSH2 gene.
  • Muir-Torre syndrome (MTS) is a rare cancer-predisposing syndrome that is autosomal dominantly inherited and characterized by the development of sebaceous skin lesions (adenomas, epitheliomas, basaliomas and carcinomas).
  • These lesions are typically associated with tumors that belong to the spectrum of hereditary nonpolyposis colorectal cancer (HNPCC) (i.e., tumors of the colorectum, endometrium, stomach or ovary).
  • Biliary malignancy in association with MTS has only rarely been reported.
  • We report a case of Muir-Torre syndrome associated with intrahepatic cholangiocarcinoma, a location not previously described, and associated with a novel missense mutation of the MSH2 gene (c.2026T > C), predicted to disrupt the function of the gene.
  • [MeSH-major] Cholangiocarcinoma / genetics. Cholangiocarcinoma / secondary. Germ-Line Mutation. Liver Neoplasms / genetics. MutS Homolog 2 Protein / deficiency. Neoplasms, Multiple Primary / genetics. Neoplastic Syndromes, Hereditary / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / surgery. Adenoma / genetics. Adenoma / surgery. Adult. Brain Neoplasms / genetics. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Carcinoma / genetics. Carcinoma / surgery. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / surgery. DNA Mutational Analysis. DNA Probes. DNA-Binding Proteins. Endometrial Neoplasms / surgery. Female. Humans. Microsatellite Instability. Mutation, Missense. Polyps / surgery. Proline / genetics. Sebaceous Gland Neoplasms / genetics. Sebaceous Gland Neoplasms / surgery. Serine / genetics. Syndrome

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17051350.001).
  • [ISSN] 1389-9600
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Probes; 0 / DNA-Binding Proteins; 452VLY9402 / Serine; 9DLQ4CIU6V / Proline; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


38. Gulia A, Altamura D, De Trane S, Micantonio T, Fargnoli MC, Peris K: Pigmented reticular structures in basal cell carcinoma and collision tumours. Br J Dermatol; 2010 Feb 1;162(2):442-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pigmented reticular structures in basal cell carcinoma and collision tumours.
  • BACKGROUND: The dermatoscopic diagnosis of basal cell carcinoma (BCC) is based on well-known specific criteria.
  • Despite the fact that a pigment network is considered a negative feature for the diagnosis of BCC, its detection in a BCC context has been reported in 2.8% of cases.
  • OBJECTIVES: To determine whether pigment networks or network-like structures might represent a pitfall for the correct diagnosis of BCC.
  • METHODS: Dermatoscopic images of 412 histopathologically proven BCCs were analysed retrospectively.
  • RESULTS: Pigment network or network-like structures were detected in 14 of 412 (3.4%) BCCs.
  • Nine of 14 BCCs presented a typical pigment network, due to the association of a BCC lesion with a naevus, solar lentigo or actinic keratosis; two BCCs located on the face showed a pseudonetwork, and three of 14 lesions displayed a network-like structure characterized by light-brown irregularly meshed short linear structures, histopathologically related to a hyperpigmentation of the basal layer of the epidermis.
  • CONCLUSIONS: The presence of a pigment network in the context of a BCC is uncommon, and it usually reflects the association of BCC with a solar lentigo, naevus or a specific location of the lesion on photodamaged skin.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Dermoscopy / methods. Melanins. Skin Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Retrospective Studies. Skin Pigmentation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19754866.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Melanins
  •  go-up   go-down


39. Paavilainen V, Aaltonen M, Tuominen J, Saari KM: Histological characteristics of basal cell carcinoma of the eyelid. Ophthalmic Res; 2007;39(1):45-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological characteristics of basal cell carcinoma of the eyelid.
  • PURPOSE: To evaluate the histological subtypes of basal cell carcinoma (BCC) of the eyelid and to determine their effect on the size, depth of invasion and need of retreatment of a nonselected patient material seen in south-western Finland.
  • METHODS: We studied the case records and the histological characteristics of BCC of the eyelid treated at the Turku University Eye Clinic during the years 1988 through 1997.
  • The material consisted 103 patients (103 BCC tumors of the eyelid).
  • RESULTS: In 78.3% of the cases, the diameter of the lesion was smaller than 10 mm.
  • The most frequent histological subtype was nodular (84.5%) followed by sclerosing (5.8%), micronodular (4.9%), keratotic (2.9%) and superficial (1.9%) types of BCC of the eyelid.
  • Only patients of the nodular subtype showed recurrences (11 cases).
  • However, some nodular types of BCC tumors smaller than 10 mm in diameter extended to a depth of more than 4.0 mm.
  • CONCLUSIONS: The nodular subtype of BCC should be regarded as a potentially invasive and recurrent tumor.
  • Histopathological examination and subtyping of all BCC tumors is recommended.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164577.001).
  • [ISSN] 0030-3747
  • [Journal-full-title] Ophthalmic research
  • [ISO-abbreviation] Ophthalmic Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


40. Alessi E, Venegoni L, Fanoni D, Berti E: Cytokeratin profile in basal cell carcinoma. Am J Dermatopathol; 2008 Jun;30(3):249-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin profile in basal cell carcinoma.
  • Origin of basal cell carcinoma (BCC) is still unclear.
  • We studied the cytokeratin (CK) profile in BCC using monoclonal antibodies against 12 CKs to further investigate the suggested origin of the tumor from follicular matrix cells or from follicular outer root sheath cells and to determine if BCC subtypes can be identified on the basis of their CK profiles.
  • Cases of pilomatricoma and samples of fetal skin served as controls to establish the CK profile in matrical cells and developing follicles during intrauterine life, that of the epidermis and cutaneous adnexa in adult life having been determined in a previous study.
  • The most significant findings were as follows: (a) CK 5 and CK 17 positivity in all the BCCs studied;.
  • (b) CK 7, CK 8, CK 18, and CK 19 positivity in 30/52, 33/52, 42/52, and 14/52 BCCs, respectively;.
  • (c) CK 14 negativity in almost all the BCCs studied; and (d) lack of CK 1 expression only in 2/2 morpheiform BCCs and 4/10 nodular BCCs.
  • The study suggests a tumorous differentiation toward follicular outer root sheath cells and, in most cases, also toward the glandular components of the pilosebaceous-apocrine unit.
  • No significant difference in the CK profile among the BCC subtypes studied was found.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Basal Cell / metabolism. Keratins / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Cell Transformation, Neoplastic. Fetus. Gestational Age. Hair Diseases / metabolism. Hair Diseases / pathology. Hair Follicle / metabolism. Hair Follicle / pathology. Humans. Keratinocytes / metabolism. Keratinocytes / pathology. Pilomatrixoma / metabolism. Pilomatrixoma / pathology. Skin / chemistry. Skin / embryology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18496426.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


41. Bechert CJ, Stern JB: Basal cell carcinoma with perineural invasion: reexcision perineural invasion? J Cutan Pathol; 2010 Mar;37(3):376-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with perineural invasion: reexcision perineural invasion?
  • BACKGROUND: Perineural invasion (PI) in basal cell and squamous cell carcinomas, especially of the head and neck, has been reported to indicate an increased morbidity.
  • Reexcision perineural invasion (RPI), a benign mimic of tumoral perineural invasion, may present a difficult histologic differential diagnosis.
  • METHODS: We surveyed the medical literature for PI occurring in basal cell carcinomas to investigate the degree to which the reported cases occurred in reexcision specimens vs. primary biopsy specimens.
  • RESULTS: We found large retrospective studies of 14,120 basal cell carcinomas evaluated for PI in which 310 cases of PI were identified (2.2%), and 20 sporadic case reports of basal cell carcinomas with PI.
  • Of 310 cases of basal cell carcinoma with PI, 196 (63%) were in reexcision specimens.
  • CONCLUSION: The high percentage of PI occurring in reexcision specimens vs. primary excisions may indicate that many of the reported cases of basal cell carcinomas with PI are actually examples of RPI.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasm Invasiveness / pathology. Neoplasm Seeding. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Humans. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Reoperation. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cutan Pathol. 2011 Jan;38(1):76-7 [20840330.001]
  • [CommentIn] J Cutan Pathol. 2012 Nov;39(11):1047-8 [22830947.001]
  • [CommentIn] J Cutan Pathol. 2011 Jan;38(1):78-9 [20860728.001]
  • (PMID = 19615028.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


42. Belliveau MJ, Coupal DJ, Brownstein S, Jordan DR, Prokopetz R: Infundibulocystic basal cell carcinoma of the eyelid in basal cell nevus syndrome. Ophthal Plast Reconstr Surg; 2010 May-Jun;26(3):147-52
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infundibulocystic basal cell carcinoma of the eyelid in basal cell nevus syndrome.
  • PURPOSE: To describe the histopathologic findings in a series of eyelid basal cell carcinomas removed from patients with basal cell nevus syndrome.
  • METHODS: Retrospective case series of 5 patients with basal cell nevus syndrome identified from our oculoplastics service.
  • The pertinent published literature on basal cell nevus syndrome and eyelid basal cell carcinoma was reviewed.
  • Twenty-three of these lesions were basal cell carcinomas.
  • The infundibulocystic variant of basal cell carcinoma was identified most commonly (57%).
  • CONCLUSIONS: Eyelid basal cell carcinomas in patients with basal cell nevus syndrome were commonly of the infundibulocystic variety in our series.
  • Infundibulocystic basal cell carcinomas, which can be clinically indistinguishable from the more common forms, are thought to be less aggressive than other types of basal cell carcinoma and are a reassuring histopathologic diagnosis.
  • It is important for the ophthalmologist and pathologist to be aware of infundibulocystic basal cell carcinomas, as they are more common in patients with basal cell nevus syndrome and may be a clue to the diagnosis of this autosomal dominant cancer-predisposition syndrome or other associated syndromes.
  • To our knowledge, this variant of basal cell carcinoma has not been previously discussed in the ophthalmic literature.
  • [MeSH-major] Basal Cell Nevus Syndrome / pathology. Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology


43. Córdoba A, Guerrero D, Larrinaga B, Iglesias ME, Arrechea MA, Yanguas JI: Bcl-2 and CD10 expression in the differential diagnosis of trichoblastoma, basal cell carcinoma, and basal cell carcinoma with follicular differentiation. Int J Dermatol; 2009 Jul;48(7):713-7
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 and CD10 expression in the differential diagnosis of trichoblastoma, basal cell carcinoma, and basal cell carcinoma with follicular differentiation.
  • BACKGROUND: Both trichoblastoma and basal cell carcinoma (BCC) of the skin are characterized morphologically by the proliferation of basaloid cells; however, BCCs are clinically associated with a more aggressive behavior.
  • An accurate diagnosis of these lesions is essential for effective, timely treatment and appropriate therapeutic decisions.
  • Bcl-2 and CD10 immunohistochemistry were performed in all cases and the patterns of expression were analyzed.
  • RESULTS: Bcl-2 is useful for the detection of BCC with diffuse expression in nests of basaloid cells, but cannot distinguish between BCC with follicular differentiation and trichoblastoma, as both lesions show the same pattern with positive and negative areas.
  • Conversely, CD10 expression can distinguish between trichoblastomas with peritumoral stromal staining and BCCs with epithelial staining.
  • If both stromal and epithelial areas are stained, these cases are classified as BCC with follicular differentiation.
  • CONCLUSIONS: CD10 is useful for distinguishing between BCC with widespread follicular differentiation and trichoblastomas.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Basal Cell / pathology. Neprilysin / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Skin Diseases / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Cell Differentiation. Cell Division. Diagnosis, Differential. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19570076.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


44. Gudbjartsson DF, Sulem P, Stacey SN, Goldstein AM, Rafnar T, Sigurgeirsson B, Benediktsdottir KR, Thorisdottir K, Ragnarsson R, Sveinsdottir SG, Magnusson V, Lindblom A, Kostulas K, Botella-Estrada R, Soriano V, Juberías P, Grasa M, Saez B, Andres R, Scherer D, Rudnai P, Gurzau E, Koppova K, Kiemeney LA, Jakobsdottir M, Steinberg S, Helgason A, Gretarsdottir S, Tucker MA, Mayordomo JI, Nagore E, Kumar R, Hansson J, Olafsson JH, Gulcher J, Kong A, Thorsteinsdottir U, Stefansson K: ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet; 2008 Jul;40(7):886-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma.
  • Fair color increases risk of cutaneous melanoma (CM) and basal cell carcinoma (BCC).
  • Recent genome-wide association studies have identified variants affecting hair, eye and skin pigmentation in Europeans.
  • Here, we assess the effect of these variants on risk of CM and BCC in European populations comprising 2,121 individuals with CM, 2,163 individuals with BCC and over 40,000 controls.
  • A haplotype near ASIP, known to affect a similar spectrum of pigmentation traits as MC1R variants, conferred significant risk of CM (odds ratio (OR) = 1.45, P = 1.2 x 10(-9)) and BCC (OR = 1.33, P = 1.2 x 10(-6)).
  • The variant in TYR encoding the R402Q amino acid substitution, previously shown to affect eye color and tanning response, conferred risk of CM (OR = 1.21, P = 2.8 x 10(-7)) and BCC (OR = 1.14, P = 6.1 x 10(-4)).
  • [MeSH-major] Agouti Signaling Protein / genetics. Carcinoma, Basal Cell / genetics. Melanoma / genetics. Monophenol Monooxygenase / genetics. Pigmentation / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Europe. Eye Color / genetics. Gene Frequency. Genetic Predisposition to Disease. Humans. Membrane Glycoproteins / genetics. Middle Aged. Neoplasm Metastasis. Odds Ratio. Oxidoreductases / genetics. Polymorphism, Single Nucleotide. Receptor, Melanocortin, Type 1 / genetics. Registries


45. Chuprov IN: [Basal-cell carcinoma of the skin]. Arkh Patol; 2007 Nov-Dec;69(6):52-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal-cell carcinoma of the skin].
  • The paper represents an overview of updated literature concerning common skin neoplasms.
  • The clinical manifestation of the basal cell carcinoma varies significantly according to the patients age, tumor size, localization and duration of the neoplastic process, histological type of the tumor, including proliferative activity and stromal reactions.
  • [MeSH-major] Carcinoma, Basal Cell. Skin Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18290385.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 53
  •  go-up   go-down


46. Filho LL, de Oliveira de Avelar Alchorne A, Pereira GC, Lopes LR, de Carvalho TC: Histological and immunohistochemical evaluation of basal cell carcinoma following curettage and electrodessication. Int J Dermatol; 2008 Jun;47(6):610-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological and immunohistochemical evaluation of basal cell carcinoma following curettage and electrodessication.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most frequent non-melanoma skin cancer.
  • Curettage and electrosurgery is probably the method most commonly used by dermatologists for the treatment of small and low risk BCCs.
  • METHODS: 20 primary BCC outpatients were studied at the Dermatology Service of Getúlio Vargas Hospital in the city of Teresina--State of Piauí--Brazil, with lesions of up to 1 cm in diameter on the face, and up to 1.5 cm elsewhere, and with no clinical signs of sclerosing and micronodular forms.
  • After two curettage and electrofulguration cycles, an incision around the resultant ulcer was made 2 mm beyond the visible bloody borders and in the base to the middle of subcutaneous fat.
  • RESULTS: There was evidence of persistent BCC in 5 of the 20 sites treated (25%): four (20%) in one quadrant and one (5%) in all four quadrants.
  • 70-100% of tumor cells expressed Ber-EP4 in all 20 BCCs.
  • CONCLUSIONS: The persistence of tumoral residues after 2 curettage and electrofulguration cycles for basal cell carcinoma was found in 5 sites treated (25%).
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Curettage. Electrosurgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm, Residual. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18477158.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / human epithelial antigen-125
  •  go-up   go-down


47. Bielsa I, Soria X, Esteve M, Ferrándiz C, Skin Cancer Study Group of Barcelonès Nord: Population-based incidence of basal cell carcinoma in a Spanish Mediterranean area. Br J Dermatol; 2009 Dec;161(6):1341-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population-based incidence of basal cell carcinoma in a Spanish Mediterranean area.
  • BACKGROUND: Considering the latitude of Spain, the reported age-adjusted incidence rates of basal cell carcinoma (BCC) in this country, similar to those of Northern Europe, are lower than expected.
  • OBJECTIVES: To estimate the actual incidence of BCC in a Mediterranean population from the eastern coast of Spain.
  • METHODS: A registry of BCC cases newly diagnosed between 16 January 2006 and 16 January 2007 was established for the population of residents in the Barcelonès Nord county (369,622 inhabitants).
  • All tumours were registered as 'definite' or 'probable' BCC cases according the existence or not of a proven microscopic diagnosis.
  • RESULTS: Among the 936 cases registered, 81.2% were classified as 'definite' BCC and 18.8% as 'probable' BCC.
  • After the age of 65 years, the BCC age-adjusted incidence rates showed a significantly higher increase in men than in women (P = 0.01).
  • Age-adjusted incidence rates revealed that BCC increases with age in both sexes, this increase being particularly evident in men older than 65 years.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Skin Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19796178.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Boza A; Carrascosa JM; Fuente MJ; González C; Gratacós R; Llagostera M; Mangas C; Martín-Urda MT; De Mena E; Mis M; Oliete R; Ribera M; Del Río R; Romaní J; Samia JC; Sola MA; Suárez JA; Toll A; Vilaltella I
  •  go-up   go-down


48. Smirnova IO, Kvetnoĭ IM, Anichkov NM, Smirnova ON, Antonova IV: [Mast cells in photolesion of the skin and basal cell cancer associated with it]. Arkh Patol; 2005 Sep-Oct;67(5):26-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mast cells in photolesion of the skin and basal cell cancer associated with it].
  • Morphofunctional features of skin mast cells located in the areas subjected to chronic UV-radiation and in the associated basal cell carcinoma with photoinjure have been studied.
  • Various immunohistochemical methods (chromogranin A, CDla, HLA-DR, CD35, Ki67, P53, Bcl-2, Mcl-1, involucrine) were used.
  • It is found that chronic UV-damage leads to mast cell hyperplasia as well as activation of their synthetic, absorption and secretory functions.
  • It is suggested that mast cell hyperplasia and increase of mast cells neuroendocrine activity provide a risk of basal cell carcinoma development.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Mast Cells / radiation effects. Mastocytosis, Cutaneous / complications. Skin / pathology. Skin Neoplasms / etiology
  • [MeSH-minor] Adult. Antigens, Surface / analysis. Biomarkers, Tumor / analysis. Female. Humans. Hyperplasia / pathology. Middle Aged. Neoplasm Proteins / analysis. Ultraviolet Rays

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16323476.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


49. Funauchi M, Yamagata T, Sugiyama M, Ikoma SY, Sakaguchi M, Kinoshita K, Kawata A: A case of antiphospholipid antibody syndrome that manifested in the course of basal cell carcinoma. Mod Rheumatol; 2007;17(2):153-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of antiphospholipid antibody syndrome that manifested in the course of basal cell carcinoma.
  • A case of antiphospholipid antibody syndrome (APS) is presented, which manifested 5 years after onset of basal cell carcinoma (BCC).
  • Because immunological abnormalities including anti-cardiolipin beta(2) glycoprotein-I antibody improved after surgical resection of BCC, it is likely that APS had occurred as a paraneoplastic syndrome with BCC.
  • This case suggests that it is necessary to investigate the presence of APS when BCC is complicated by some coagulopathies.

  • Genetic Alliance. consumer health - Antiphospholipid Syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17437172.001).
  • [ISSN] 1439-7595
  • [Journal-full-title] Modern rheumatology
  • [ISO-abbreviation] Mod Rheumatol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid
  •  go-up   go-down


50. Lupi O: Correlations between the Sonic Hedgehog pathway and basal cell carcinoma. Int J Dermatol; 2007 Nov;46(11):1113-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlations between the Sonic Hedgehog pathway and basal cell carcinoma.
  • The family received their name because when the D. melanogaster HH protein malfunctions the mutant fly ends up looking like a small prickly ball, similar to a curled up hedgehog.
  • The Sonic hedgehog (SHH) pathway is implicated in the etiology of the most common human cancer, the basal cell carcinoma (BCC).
  • Mutations in the receptor of SHH, the patched gene (PTCH), have been characterized in sporadic BCCs as well as those from patients with the rare genetic syndrome nevoid BCC.
  • Human PTCH is mutated in sporadic as well as hereditary BCCs, and inactivation of this gene is probably a necessary if not sufficient step for tumorigenesis.
  • Delineation of the biochemical pathway in which PTCH functions may lead to rational medical therapy for skin cancer and possibly other tumors.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Forkhead Transcription Factors / metabolism. Hedgehog Proteins / metabolism. Receptors, Cell Surface / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic. Humans. Mutation. Receptors, G-Protein-Coupled / genetics. Receptors, G-Protein-Coupled / metabolism. Signal Transduction. Veratrum Alkaloids / pharmacology

  • Genetics Home Reference. consumer health - PTCH1 gene.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988327.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Forkhead Transcription Factors; 0 / Hedgehog Proteins; 0 / Receptors, Cell Surface; 0 / Receptors, G-Protein-Coupled; 0 / SHH protein, human; 0 / SMO protein, human; 0 / Veratrum Alkaloids; 0 / patched receptors; ZH658AJ192 / cyclopamine
  • [Number-of-references] 35
  •  go-up   go-down


51. Kuijpers DI, Thissen MR, Berretty PJ, Ideler FH, Nelemans PJ, Neumann MH: Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatol Surg; 2007 May;33(5):579-87
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma.
  • BACKGROUND: Both cryosurgery, with and without prior curettage, and surgical excision (SE) are common therapeutic strategies for basal cell carcinoma (BCC).
  • OBJECTIVE: The objective was to compare the efficacy between curettage plus cryosurgery (C&C) and SE in nonaggressive BCC of the head and neck.
  • CONCLUSION: These data reflect the outcome of the first randomized controlled trial with long-term follow-up in the treatment of BCC, comparing C&C with SE.
  • Owing to the trend toward lower recurrence rates, better cosmetic results, and reduced wound healing time, we believe that SE should be preferred to C&C in the treatment of primary, nonaggressive BCC of the head and neck.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Neoplasm Recurrence, Local / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cryosurgery / methods. Curettage / methods. Disease-Free Survival. Face. Female. Humans. Male. Middle Aged. Netherlands. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatol Surg. 2008 Apr;34(4):582 [18248484.001]
  • (PMID = 17451581.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


52. Lee DA, Ratner D: Economic impact of preoperative curettage before Mohs micrographic surgery for basal cell carcinoma. Dermatol Surg; 2006 Jul;32(7):916-22; discussion 922-3
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Economic impact of preoperative curettage before Mohs micrographic surgery for basal cell carcinoma.
  • BACKGROUND: The role of curettage before Mohs micrographic surgery for basal cell carcinoma (BCC) remains controversial.
  • Preoperative curettage may allow the surgeon to better delineate the subclinical extensions of high-risk BCCs, thereby enabling a more precise first-stage excision around tumor-containing tissue.
  • OBJECTIVE: To assess the economic impact of preoperative curettage for high-risk BCCs treated with Mohs micrographic surgery on patients, providers, and insurers.
  • New York City Medicare and Standard reimbursement rates were used to approximate the cost of an additional stage of Mohs surgery for high-risk BCCs.
  • Thus, if the Mohs surgeon estimates that the time required to remove a second stage is 75% of that of the first stage, the time savings with preoperative curettage equals 75% of the duration of a one-stage Mohs surgery.
  • Similarly, when a second stage requires 50 or 25% of the time needed to complete the first stage, the time saved equals 50 or 25% of the duration of a one-stage Mohs surgery.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Curettage / economics. Mohs Surgery / economics. Preoperative Care / economics. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatol Surg. 2007 Aug;33(8):1000 [17661950.001]
  • (PMID = 16875474.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Del Sordo R, Cavaliere A, Sidoni A: Basal cell carcinoma with matrical differentiation: expression of beta-catenin [corrected] and osteopontin. Am J Dermatopathol; 2007 Oct;29(5):470-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with matrical differentiation: expression of beta-catenin [corrected] and osteopontin.
  • Basal cell carcinoma with matrical differentiation is an extremely rare variant.
  • To date, only 12 cases have been described in the literature.
  • This tumor is a typical basal cell carcinoma with basaloid nests containing shadow cells identical to those of pilomatricoma and pilomatrical carcinoma.
  • We present two additional cases and have investigated the immunoprofile of .
  • The morphological and immunohistochemical features of these cases that we have found suggest that basal cell carcinomas with matrical differentiation belong to a spectrum of lesions deriving from hair follicles in which .
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Cell Transformation, Neoplastic / pathology. Osteopontin / metabolism. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. beta Catenin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Dermatopathol. 2008 Jun;30(3):317
  • (PMID = 17890917.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / beta Catenin; 106441-73-0 / Osteopontin
  •  go-up   go-down


54. Aguayo-Leiva IR, Ríos-Buceta L, Jaén-Olasolo P: [Surgical vs nonsurgical treatment of basal cell carcinoma]. Actas Dermosifiliogr; 2010 Oct;101(8):683-92
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical vs nonsurgical treatment of basal cell carcinoma].
  • [Transliterated title] Tratamiento quirúrgico vs. no quirúrgico en el carcinoma basocelular.
  • Numerous therapeutic options are now available for the treatment of basal cell carcinoma.
  • Then, based on the evidence reviewed, we attempt to provide an outline of the therapeutic strategies recommended in basal cell carcinoma, and the approach to be used in specific situations.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Cryosurgery. Fluorouracil / therapeutic use. Follow-Up Studies. Hedgehog Proteins / antagonists & inhibitors. Humans. Interferons / therapeutic use. Laser Therapy. Mohs Surgery. Neoplasm Recurrence, Local. Photochemotherapy. Phytotherapy. Plant Preparations / therapeutic use. Risk Factors. Semecarpus. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Actas Dermosifiliogr. 2011 Oct;102(8):633-4 [21798484.001]
  • (PMID = 20965011.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Hedgehog Proteins; 0 / Plant Preparations; 0 / SHH protein, human; 9008-11-1 / Interferons; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  •  go-up   go-down


55. Bertelmann E, Rieck P, Hartmann C: [Reconstruction of skin defects in the eyelid and periorbital region using four triangular advancement flaps. An alternative to free skin grafts]. Ophthalmologe; 2006 Feb;103(2):120-3
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reconstruction of skin defects in the eyelid and periorbital region using four triangular advancement flaps. An alternative to free skin grafts].
  • PURPOSE: This report presents a procedure as an alternative to free skin grafts for reconstruction of rhomboid skin defects in the lid region.
  • METHOD: Ten consecutively treated patients were included who had skin defects after resection of eyelid tumors such as basaliomas.
  • The skin defects were rhomboid and had the same horizontal and vertical diameter (medium 1.5 cm) and were therefore too large for a horizontal advancement flap.
  • The defects were closed by preparation of four triangular skin flaps that were sutured crosswise into the defect.
  • RESULTS: The procedure was adequate for reconstruction of the defect in all ten cases.
  • There were no lid malpositions and the cosmetic results were favorable in all cases.
  • The medium operation time was significantly shorter in comparison to free skin grafts.
  • CONCLUSIONS: Application of free skin grafts is a standard procedure for reconstruction of anterior lamellar lid defects.
  • [MeSH-major] Eyelids / surgery. Ophthalmologic Surgical Procedures / instrumentation. Ophthalmologic Surgical Procedures / methods. Reconstructive Surgical Procedures / instrumentation. Reconstructive Surgical Procedures / methods. Skin Abnormalities / surgery. Surgical Flaps
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Skin Transplantation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16078064.001).
  • [ISSN] 0941-293X
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


56. Ly E, Piot O, Durlach A, Bernard P, Manfait M: Polarized Raman microspectroscopy can reveal structural changes of peritumoral dermis in basal cell carcinoma. Appl Spectrosc; 2008 Oct;62(10):1088-94
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polarized Raman microspectroscopy can reveal structural changes of peritumoral dermis in basal cell carcinoma.
  • This technique is used for the first time on a human skin section to probe the molecular modifications of the surrounding dermis in superficial basal cell carcinoma.
  • We see polarized Raman microspectroscopy as a potential tool that could be implemented for clinical analyses to guide clinicians and surgeons in the treatment of aggressive skin cancers.
  • The information obtainable could also help better elucidate the molecular mechanisms induced in basal cell carcinoma development.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Microscopy, Polarization / methods. Skin Neoplasms / pathology. Spectrum Analysis, Raman / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18926017.001).
  • [ISSN] 0003-7028
  • [Journal-full-title] Applied spectroscopy
  • [ISO-abbreviation] Appl Spectrosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Adegboyega PA, Rodriguez S, McLarty J: Stromal expression of actin is a marker of aggressiveness in basal cell carcinoma. Hum Pathol; 2010 Aug;41(8):1128-37
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal expression of actin is a marker of aggressiveness in basal cell carcinoma.
  • Basal cell carcinoma is a very common malignant skin tumor that rarely metastasizes but is often locally aggressive.
  • In a number of studies conducted by different investigators, Bcl2, beta-catenin, cyclin D1, hMSH2, and alpha-smooth muscle actin have been reported to have potential for predicting basal cell carcinoma aggressiveness.
  • We therefore studied the expression and topographic locations (tumor versus stroma) of all these gene products in a group of clinically proven aggressive basal cell carcinomas (n = 30) and randomly selected control cases of nonaggressive basal cell carcinomas (n = 33).
  • These data show conclusively that aggressive basal cell carcinomas express alpha-smooth muscle actin in the stroma, whereas nonaggressive basal cell carcinomas express alpha-smooth muscle actin in the tumor cells, and that stromal expression of alpha-smooth muscle actin is an accurate, reliable, and easy to use marker of aggressiveness in basal cell carcinomas and can be used in clinical practice for surgical therapeutic decisions.
  • [MeSH-major] Actins / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Basal Cell / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology. Stromal Cells / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20381122.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / beta Catenin; 136601-57-5 / Cyclin D1; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


58. Kanitakis J, Chouvet B: Granular-cell basal cell carcinoma of the skin. Eur J Dermatol; 2005 Jul-Aug;15(4):301-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular-cell basal cell carcinoma of the skin.
  • Granular cell basal cell carcinoma (GBCC) is a very rare variant of BCC, of which ten cases have been reported in the literature.
  • We describe here a new case of GBCC studied immunohistochemically.
  • The tumor developed on the face of a 71-year old man and showed typical features of GBCC, i.e. a tumor reminiscent of nodular BCC consisting of cells with a granular eosinophilic cytoplasm.
  • [MeSH-major] Adenocarcinoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Immunohistochemistry. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16048765.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 12
  •  go-up   go-down


59. Bariani RL, Nahas FX, Barbosa MV, Farah AB, Ferreira LM: Basal cell carcinoma: an updated epidemiological and therapeutically profile of an urban population. Acta Cir Bras; 2006 Mar-Apr;21(2):66-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma: an updated epidemiological and therapeutically profile of an urban population.
  • PURPOSE: To describe the epidemiological profile of basal cell carcinoma patients at a private hospital in São Paulo and to evaluate the treatment adopted.
  • METHODS: A prospective study of 202 patients, on which 253 lesions were diagnosed for histopathological exam as basal cell carcinoma within the period of January 2001 to September 2003, in the Plastic Surgery Residency Program at the Hospital Jaraguá.
  • RESULTS: The incidence of basal cell carcinoma was 126 cases per 100,000 patients in a period of 32 months (36 cases per 100,000 patients/year).
  • Exposition to ultraviolet radiation was reported by 77% of the patients and the most frequent location of tumors was on the face (71.2% of the cases).
  • Actinic keratosis and a history of skin cancer were reported in 43.6% and in 25% of the cases, respectively.
  • The adopted treatment was surgery in 99.4% of the cases and only one patient was treated with radiotherapy.
  • The recurrence rate was 2% (5 cases).
  • There were no cases with metastasis or fatal outcome.
  • CONCLUSIONS: The factors related to the development of basal cell cancer which were significantly present in the population surveyed were: older age, white individuals, phototypes I and II, presence of actinic keratosis, previous history of non-melanoma skin cancer and exposure to ultra-violet rays both in recreational and in occupational form.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16583057.001).
  • [ISSN] 0102-8650
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


60. Son KD, Kim TJ, Lee YS, Park GS, Han KT, Lim JS, Kang CS: Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin. J Surg Oncol; 2008 Jun 1;97(7):615-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin.
  • BACKGROUND: This study evaluates several tumor-related markers to examine the expression pattern of markers according to the invasiveness and histopathologic differentiation of squamous cell carcinoma and basal cell carcinoma.
  • METHODS: Ninety-four cases of squamous cell carcinoma and 108 cases of basal cell carcinoma using tissue array in order to determine correlations between the expression of Ki-67, p53, EGFR, CD44v6, MMP-1 and MMP-3, invasiveness and histologic differentiation.
  • RESULTS: The depth of invasion showed a correlation with CD44v6 expression of tumor cell in both squamous cell carcinoma and basal cell carcinoma (P = 0.009, P = 0.036, respectively) and with the MMP-1 expression of stromal cell in squamous cell carcinoma (P = 0.010).
  • The differentiation of squamous cell carcinoma was correlated with Ki-67 index.
  • The loss of palisading arrangement in basal cell carcinoma was correlated with the MMP-1 expression of stromal cells (P = 0.045).
  • CONCLUSIONS: CD44v6 and MMP-1, expressed in tumor cells and stromal cells respectively, are significant markers associated with the invasiveness of tumors in squamous cell carcinoma and basal cell carcinoma of the skin and that it will be helpful to evaluate the invasiveness by measuring the expression of these markers.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD44 / biosynthesis. Female. Genes, erbB-1. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Male. Matrix Metalloproteinase 1 / biosynthesis. Matrix Metalloproteinase 3 / biosynthesis. Middle Aged. Neoplasm Invasiveness. Tumor Suppressor Protein p53 / biosynthesis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404670.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44 protein, human; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


61. Saini R, Sarnoff DS: Basal cell carcinoma of the vulva presenting as unilateral pruritus. J Drugs Dermatol; 2008 Mar;7(3):288-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the vulva presenting as unilateral pruritus.
  • Basal cell carcinoma (BCC) is the most common human malignancy, which often occurs as a result of ultraviolet light on sun-exposed areas.
  • A more rare location for the presentation of BCC is the non-sun-exposed genital area, where squamous cell cancer occurs frequently in the setting of human papilloma virus and chronic inflammatory lesions (i.e., lichen sclerosus et atrophicus).
  • A delay in diagnosis can result in wider surgical margins and potential recurrences.
  • We present a case of BCC of the vulva with involvement of the clitoris presenting with unilateral pruritus and treated as an allergic contact dermatitis with topical corticosteroids.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Diagnostic Errors. Pruritus / etiology. Vulvar Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Dermatitis, Allergic Contact / diagnosis. Diagnosis, Differential. Female. Humans. Vulva / pathology

  • MedlinePlus Health Information. consumer health - Itching.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18380212.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Piérard-Franchimont C, Nikkels AF, Paquet P, Quatresooz P, Piérard GE: [How I treat ... basal cell carcinoma by imiquimod]. Rev Med Liege; 2005 Apr;60(4):207-9
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [How I treat ... basal cell carcinoma by imiquimod].
  • [Transliterated title] Comment je traite.... Un carcinome basocellulaire par l'imiquimod topique (Aldara).
  • Basal cell carcinoma is the most frequent cancer in humans.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943094.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  • [Number-of-references] 32
  •  go-up   go-down


63. Zhang XB, Zhang SQ, Li CX, Huang ZM, Luo YW: Acitretin systemic and retinoic acid 0.1% cream supression of basal cell carcinoma. Dermatol Reports; 2010 Jan 18;2(1):e4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acitretin systemic and retinoic acid 0.1% cream supression of basal cell carcinoma.
  • Retinoids have been used for years as monotherapy and/or in combination for treatment and suppression of cutaneous malignancies in patients with basal cell nevus syndrome, xeroderma pigmentosum, or cutaneous T-cell lymphoma (CTCL) basal cell carcinoma (BCC).
  • We report 4 cases with BCC confirmed by histopathology who were treated by short-term systemic acitretin combined with retinoic acid 0.1% cream.
  • The 4 cases with BCC showed good response to the treatment without severe adverse effects during treatment and follow-up.
  • The finding suggests that acitretin may be an appropriate treatment option for elderly patients who require less invasive treatment for BCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25386240.001).
  • [ISSN] 2036-7392
  • [Journal-full-title] Dermatology reports
  • [ISO-abbreviation] Dermatol Reports
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC4211482
  • [Keywords] NOTNLM ; acitretin / basal cell carcinoma.
  •  go-up   go-down


64. Farhi D, Dupin N, Palangié A, Carlotti A, Avril MF: Incomplete excision of basal cell carcinoma: rate and associated factors among 362 consecutive cases. Dermatol Surg; 2007 Oct;33(10):1207-14
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incomplete excision of basal cell carcinoma: rate and associated factors among 362 consecutive cases.
  • BACKGROUND: Reported rates of incomplete excision of basal cell carcinoma (BCC) range from 4% to 16.6%.
  • OBJECTIVE: The objective was to assess, in clinical practice, the rate and the factors associated with pathologically reported incomplete excision of BCC.
  • METHODS: In this retrospective monocentric study, data from all surgically excised BCCs during the year 2004 were computerized.
  • Age, sex, number of BCC excised during the same surgical session, BCC location, pathologic types, and involvement of surgical margins were analyzed.
  • A total of 52.7% of the 362 BCCs were located on the face (including nose, 10%; eyelids, 4.2%; lips, 2%; and ears, 2.2%).
  • Incomplete excisions occurred in 10.3% of the cases including 8.6% of positive lateral margins and 2.5% of positive deep margins.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Neoplasm Recurrence, Local / surgery. Outcome Assessment (Health Care). Skin Neoplasms / surgery. Surgical Procedures, Operative / standards

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17903153.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


65. Rodriguez C, Barriuso V, Chan LS: Extensive basal cell carcinoma with probable bone metastasis. Cutis; 2007 Jul;80(1):60-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive basal cell carcinoma with probable bone metastasis.
  • Metastasis of basal cell carcinoma (BCC) rarely occurs.
  • Few cases have been reported in the literature; those cases reported generally resulted from chronic, extensive, recurrent lesions on the head or neck.
  • With regard to bone metastases, several case reports have demonstrated similar clinical features indicative of osseous involvement.
  • We present a case report of a patient with an extensive BCC with histologic documentation and probable bone metastasis of BCC.
  • Clinical and radiographic features of this case were consistent with previously reported patients.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Basal Cell / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17725067.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


66. Jadotte YT, Sarkissian NA, Kadire H, Lambert WC: CASE REPORT Superficial Spreading Basal Cell Carcinoma of the Face: A Surgical Challenge. Eplasty; 2010;10:e46

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CASE REPORT Superficial Spreading Basal Cell Carcinoma of the Face: A Surgical Challenge.
  • OBJECTIVE: We present the case of a white man with a facial nodule suspicious for basal cell carcinoma.
  • METHODS: Biopsy revealed clusters of basaloid tumor cells with peripheral palisading, consistent with a superficial spreading variant of basal cell carcinoma.
  • However, since it was a superficial spreading basal cell carcinoma, this was followed by topical imiquimod treatment.
  • CONCLUSION: Topical chemotherapy with imiquimod or 5-fluorouracil may be valuable alternatives or adjuncts, given the increased likelihood of recurrence after surgical excision of superficial spreading basal cell carcinoma.
  • Mohs surgery is of limited value in the management of superficial spreading basal cell carcinoma because it characteristically shows areas of uninvolved skin between tumor nests.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2003 Feb;148(2):195-202 [12588368.001]
  • [Cites] J Invest Dermatol. 2003 Jun;120(6):1087-93 [12787139.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):141-7 [15270883.001]
  • [Cites] J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):468-73 [15761425.001]
  • [Cites] J Am Acad Dermatol. 2005 Sep;53(3):445-51 [16112351.001]
  • [Cites] Dermatol Surg. 2009 Sep;35(9):1349-54 [19500127.001]
  • [Cites] Br J Nurs. 2009 Jan 8-21;18(1):8-16 [19127226.001]
  • [Cites] J Chin Med Assoc. 2006 Aug;69(8):364-71 [16970272.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(1):CD003412 [17253489.001]
  • [Cites] Drugs. 2007;67(6):915-34 [17428108.001]
  • [Cites] Acta Clin Croat. 2008 Mar;47(1):25-30 [18714644.001]
  • [Cites] Int J Dermatol. 2008 Oct;47(10):1015-8 [18986346.001]
  • [Cites] Br J Dermatol. 2006 Aug;155(2):401-7 [16882181.001]
  • (PMID = 20596236.001).
  • [ISSN] 1937-5719
  • [Journal-full-title] Eplasty
  • [ISO-abbreviation] Eplasty
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2890390
  •  go-up   go-down


67. Arits AH, Parren LJ, van Marion AM, Sommer A, Frank J, Kelleners-Smeets NW: Basal cell carcinoma and trichoepithelioma: a possible matter of confusion. Int J Dermatol; 2008 Nov;47 Suppl 1:13-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma and trichoepithelioma: a possible matter of confusion.
  • Difficulty in differentiation between a solitary basal cell carcinoma, which is known as a malign skin lesion and a benign trichoepithelioma, is a frequent problem in all day dermatologic practice.
  • Clinically as well as histopathologically there are a lot of resemblances between these skin tumors.
  • By means of two real life cases, we give here an overview of the possible problems and appliances in distinguishing these two entities; at the end we do some recommendation about the policy.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Back. Biopsy. Diagnosis, Differential. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18986478.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Thirumaran RK, Bermejo JL, Rudnai P, Gurzau E, Koppova K, Goessler W, Vahter M, Leonardi GS, Clemens F, Fletcher T, Hemminki K, Kumar R: Single nucleotide polymorphisms in DNA repair genes and basal cell carcinoma of skin. Carcinogenesis; 2006 Aug;27(8):1676-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single nucleotide polymorphisms in DNA repair genes and basal cell carcinoma of skin.
  • In addition to environmental exposures like UV radiation and, in some cases, arsenic contamination of drinking water, genetic factors may also influence the individual susceptibility to basal cell carcinoma of skin (BCC).
  • In the present study, 529 cases diagnosed with BCC and 533 controls from Hungary, Romania and Slovakia were genotyped for one polymorphism in each of seven DNA repair genes.
  • The variant allele for T241M (C>T) polymorphism in the XRCC3 gene was associated with a decreased cancer risk [odds ratio (OR), 0.73; 95% confidence interval (CI), 0.61-0.88; P = 0.0007, multiple testing corrected P = 0.004].
  • The risk of multiple BCC was significantly lower among variant allele carriers than in non-carriers (P = 0.04).
  • Men homozygous for the C-allele for E185Q (G>C) polymorphism in the NBS1 gene showed an increased BCC risk (OR, 2.19; 95% CI, 1.23-3.91), but not women (OR, 0.84; 95% CI, 0.49-1.47).
  • The data from this study show overall risk modulation of BCC by variant allele for T241M polymorphism in XRCC3 and gender-specific effect by E185Q polymorphism in NBS1.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. DNA Repair. Neoplasm Proteins / genetics. Polymorphism, Single Nucleotide. Skin Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Cell Cycle Proteins / genetics. Child. Child, Preschool. Female. Genetic Predisposition to Disease. Genotype. Humans. Hungary / epidemiology. Male. Middle Aged. Nuclear Proteins / genetics. Odds Ratio. Risk Factors. Romania / epidemiology. Slovakia / epidemiology. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16501254.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / NBN protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins
  •  go-up   go-down


69. Kovarik CL, Stewart D, Barnard JJ: Lethal basal cell carcinoma secondary to cerebral invasion. J Am Acad Dermatol; 2005 Jan;52(1):149-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lethal basal cell carcinoma secondary to cerebral invasion.
  • Intracranial invasion by a basal cell carcinoma on the scalp is extremely rare.
  • We present an autopsy case of a 57-year-old woman who developed a large destructive basal cell carcinoma with extension through the calvarium and compression of the dura.
  • We compare 7 similar cases reported in the literature and review the risks for development of these aggressive fatal basal cell carcinomas on the scalp.
  • [MeSH-major] Brain Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Scalp. Skin Neoplasms / pathology
  • [MeSH-minor] Autopsy. Female. Humans. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15627099.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


70. Lee S, Cnaan RB, Paramanathan N, Davies M, Benger R, Ghabrial R: Subconjunctival "ring" recurrence of Basal cell carcinoma of the globe. Ophthal Plast Reconstr Surg; 2010 Mar-Apr;26(2):117-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subconjunctival "ring" recurrence of Basal cell carcinoma of the globe.
  • Basal cell carcinoma is the most common indication for orbital exenteration.
  • The recurrence rate of BCC removed with microscopically controlled histology sections is up to 6%.
  • The authors describe the recurrence of a lower eyelid BCC resected with microscopic control that did not manifest itself until 15 years later as a subconjunctival lesion, encircling the globe, and without apparent skin involvement.
  • BCC can present in any manner following surgery, and therefore, judicious follow-up is necessary even after microscopically controlled resection.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Conjunctival Neoplasms / pathology. Eyelid Neoplasms / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Invasiveness. Orbit Evisceration. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305512.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


71. McNaughton SA, Marks GC, Gaffney P, Williams G, Green AC: Antioxidants and basal cell carcinoma of the skin: a nested case-control study. Cancer Causes Control; 2005 Jun;16(5):609-18
Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antioxidants and basal cell carcinoma of the skin: a nested case-control study.
  • OBJECTIVE: To investigate the relationship between basal cell carcinoma (BCC) and antioxidant nutrients, specifically carotenoids, vitamin E and selenium.
  • METHODS: The Nambour Skin Cancer Study is an ongoing, community-based study of randomly selected adult residents of a township in sub-tropical Queensland, Australia.
  • Using a nested case-control design, incident cases of BCC (n=90) were compared with age and sex matched controls (n=90).
  • Other determinants of skin cancer including sun exposure were also considered.
  • Dietary intakes were adjusted for energy intake, and serum carotenoids and vitamin E were adjusted for serum cholesterol.
  • RESULTS AND CONCLUSIONS: In this prospective study no significant associations were found between BCC and carotenoids, vitamin E or selenium, as measured by serum biomarkers or dietary intake, although there was a suggestion of a positive association with lutein intake.
  • [MeSH-major] Antioxidants / administration & dosage. Carcinoma, Basal Cell / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Australia / epidemiology. Biomarkers / blood. Carotenoids / administration & dosage. Carotenoids / blood. Case-Control Studies. Diet Surveys. Dietary Supplements. Female. Humans. Logistic Models. Male. Middle Aged. Prospective Studies. Selenium / administration & dosage. Selenium / blood. Vitamin E / administration & dosage. Vitamin E / blood

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986117.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers; 1406-18-4 / Vitamin E; 36-88-4 / Carotenoids; H6241UJ22B / Selenium
  •  go-up   go-down


72. Fan YS, Carr RA, Sanders DS, Smith AP, Lazar AJ, Calonje E: Characteristic Ber-EP4 and EMA expression in sebaceoma is immunohistochemically distinct from basal cell carcinoma. Histopathology; 2007 Jul;51(1):80-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristic Ber-EP4 and EMA expression in sebaceoma is immunohistochemically distinct from basal cell carcinoma.
  • AIMS: There is considerable overlap between the histological features of sebaceoma and basal cell carcinoma (BCC).
  • The distinction between these two tumours is important due to the often more locally aggressive nature of BCC and the association of sebaceoma with the Muir-Torre syndrome.
  • The aim of this study was to describe the immunohistochemical reactivity of the cells in sebaceoma to Ber-EP4 and epithelial membrane antigen (EMA) and investigate the utility of this panel to differentiate sebaceoma from basal cell carcinoma.
  • A single case exhibited focal weak Ber-EP4 staining, predominantly in mature sebocytes and in < 10% of the tumour cells.
  • EMA was not expressed in the germinative cells of sebaceoma, but was expressed strongly in approximately 50% of mature sebocytes in all cases and highlighted the cytoplasmic vacuoles.
  • We reviewed the immunoreactivity of 51 cases of nodular BCCs and found moderate or strong BerEP4 expression in all cases with never less than 20% of the tumour staining.
  • Expression of EMA was uncommon in BCC (moderate or strong in 8%) and was confined to keratotic or squamoid areas.
  • CONCLUSION: The use of Ber-EP4 in combination with EMA, both widely used immunomarkers in histopathology, is a helpful aid in distinguishing sebaceoma from nodular BCC.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Basal Cell / metabolism. Mucin-1 / metabolism. Neoplasms, Adnexal and Skin Appendage / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Sebaceous Glands / metabolism. Sebaceous Glands / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593083.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / human epithelial antigen-125
  •  go-up   go-down


73. Jovanović M, Brasanac D, Rasulić L, Colić M, Stojicić M, Malis M: [The excision width in surgical treatment of basal cell carcinoma]. Acta Chir Iugosl; 2006;53(3):53-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The excision width in surgical treatment of basal cell carcinoma].
  • Basal cell carcinoma originates from pluripotent cells of basal layer of epiderm, external covering of hair follicles, sebaceous glands or other skin adnexa.
  • There are several types of basal cell carcinomas that may be manifested in over 12 clinical forms.
  • The analysis included 250 patients of both gender and different age, operated for basal cell carcinoma.
  • Clinical characteristics of basal cell carcinoma and the width of the excision were described.
  • It was concluded that the width of the excision of basal cell cancer was in relation to histological type.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17338201.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


74. Christensen E, Skogvoll E, Viset T, Warloe T, Sundstrøm S: Photodynamic therapy with 5-aminolaevulinic acid, dimethylsulfoxide and curettage in basal cell carcinoma: a 6-year clinical and histological follow-up. J Eur Acad Dermatol Venereol; 2009 Jan;23(1):58-66
Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with 5-aminolaevulinic acid, dimethylsulfoxide and curettage in basal cell carcinoma: a 6-year clinical and histological follow-up.
  • OBJECTIVE: To investigate long-term clinical, histological and cosmetic follow-up results in basal cell carcinoma (BCC) after PDT, including treatment response related to patients and lesion characteristics.
  • MATERIALS AND METHODS: A longitudinal study of 44 patients with 60 histologically verified BCC tumours, treated with one or two sessions of dimethylsulfoxide (DMSO)-supported 5-aminolaevulinic acid--PDT following curettage, was performed.
  • At 72 months, 43 of 53 lesions remained disease-free (81%); 68% remained after one treatment session, and 91% remained after two treatment sessions.
  • The cosmetic outcome at 72 months was rated as good or excellent by patients and investigators in more than 90% of evaluated cases.
  • CONCLUSION: DMSO-PDT following curettage is an effective treatment for BCC, with favourable long-term clinical, histopathological and cosmetic results.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Carcinoma, Basal Cell / drug therapy. Dimethyl Sulfoxide / therapeutic use. Photochemotherapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803580.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 88755TAZ87 / Aminolevulinic Acid; YOW8V9698H / Dimethyl Sulfoxide
  •  go-up   go-down


75. Ji J, Wernli M, Mielgo A, Buechner SA, Erb P: Fas-ligand gene silencing in basal cell carcinoma tissue with small interfering RNA. Gene Ther; 2005 Apr;12(8):678-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fas-ligand gene silencing in basal cell carcinoma tissue with small interfering RNA.
  • Basal cell carcinoma (BCC) is the most frequent cancer in the Caucasian population.
  • Cells of BCC strongly express Fas-ligand (FasL), a member of the tumor necrosis family, which induces apoptosis in Fas receptor-expressing cells.
  • It has been suggested that by expression of FasL, BCC cells may evade the attack of Fas-positive immune effector cells allowing the tumor to expand.
  • Thus, downregulation of FasL should prime BCC to the assault of immune effector cells.
  • We demonstrate that a specific siRNA efficiently downregulates FasL not only in FasL-positive indicator cells but also in surgically excised BCC tissue at both the protein and the mRNA level.
  • [MeSH-major] Antigens, CD95 / genetics. Carcinoma, Basal Cell / therapy. Gene Silencing. Genetic Therapy / methods. RNA, Small Interfering / administration & dosage. Transfection / methods
  • [MeSH-minor] Cell Line, Tumor. Flow Cytometry. Green Fluorescent Proteins. Humans. Immunohistochemistry / methods. In Situ Hybridization / methods. Microscopy, Confocal. Reverse Transcriptase Polymerase Chain Reaction. Rhodamines

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15660112.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / RNA, Small Interfering; 0 / Rhodamines; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


76. Olmedo JM, Warschaw KE, Schmitt JM, Swanson DL: Optical coherence tomography for the characterization of basal cell carcinoma in vivo: a pilot study. J Am Acad Dermatol; 2006 Sep;55(3):408-12
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optical coherence tomography for the characterization of basal cell carcinoma in vivo: a pilot study.
  • OBJECTIVE: The purpose of this pilot study was to define and characterize basal cell carcinoma by using optical coherence tomography.
  • METHODS: Twenty-three patients with 49 lesions clinically suggestive of superficial basal cell carcinoma were recruited.
  • RESULTS: Basal cell carcinoma was identified in 27 patients; all 27 had optical coherence tomographic images for comparison.
  • Of the remainder, 20 sites matched the histologic features seen on light microscopy, with excellent correlation between optical coherence tomographic images and histopathologic features of superficial, nodular, micronodular and infiltrative basal cell carcinomas.
  • CONCLUSIONS: Optical coherence tomography technology has potential for the diagnosis and histopathologic characterization of basal cell cancer.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Skin Neoplasms / diagnosis. Tomography, Optical Coherence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16908344.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Lorenzini M, Gatti S, Giannitrapani A: Giant basal cell carcinoma of the thoracic wall: a case report and review of the literature. Br J Plast Surg; 2005 Oct;58(7):1007-10
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant basal cell carcinoma of the thoracic wall: a case report and review of the literature.
  • Giant basal cell carcinoma is a rare skin tumour with aggressive biological behaviour, and deep invasion and metastasis have been reported.
  • The authors describe a giant basal cell carcinoma involving the anterior chest wall.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology. Thoracic Neoplasms / pathology. Thoracic Wall
  • [MeSH-minor] Aged, 80 and over. Humans. Male. Mediastinum / pathology. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Plast Reconstr Aesthet Surg. 2006;59(7):783-4 [16782583.001]
  • (PMID = 16043154.001).
  • [ISSN] 0007-1226
  • [Journal-full-title] British journal of plastic surgery
  • [ISO-abbreviation] Br J Plast Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 33
  •  go-up   go-down


78. Sapijaszko MJ: Imiquimod 5% cream (Aldara) in the treatment of basal cell carcinoma. Skin Therapy Lett; 2005 Jul-Aug;10(6):2-5
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod 5% cream (Aldara) in the treatment of basal cell carcinoma.
  • Skin cancer, the most common human cancer, is now a global epidemic.
  • The most prevalent form of nonmelanoma skin cancer is basal cell carcinoma (BCC), the incidence of which continues to increase prompting development of new treatment modalities designed to add or complement current therapies.
  • Although destructive modalities continue to be an important treatment options for BCC, nondestructive measures are a welcome addition to our therapeutic choices.
  • It enhances both the innate and acquired immune response, and has successfully treated both superficial and nodular basal cell carcinomas through the localized activation of elaborate immune response.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292452.001).
  • [ISSN] 1201-5989
  • [Journal-full-title] Skin therapy letter
  • [ISO-abbreviation] Skin Therapy Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  • [Number-of-references] 14
  •  go-up   go-down


79. Tanese K, Fukuma M, Ishiko A, Sakamoto M: Endothelin-2 is upregulated in basal cell carcinoma under control of Hedgehog signaling pathway. Biochem Biophys Res Commun; 2010 Jan 1;391(1):486-91
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endothelin-2 is upregulated in basal cell carcinoma under control of Hedgehog signaling pathway.
  • Basal cell carcinoma (BCC) is a common malignant skin tumor that frequently has aberrant activation of the Hedgehog (HH) signaling pathway.
  • We show here that endothelin-2 (ET-2) is overexpressed in BCC under the control of HH signaling.
  • By real-time quantitative RT-PCR analysis, significant expression of ET-2 mRNA was observed in 19 of 20 cases (95%) compared to normal skin.
  • In addition, inhibition of the HH signaling pathway in a mouse BCC cell line downregulated endogenous ET-2, and activation of HH signaling in mouse embryonic fibroblast upregulated endogenous ET-2.
  • These data indicate that ET-2 is a direct target gene of HH signaling in BCC.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Endothelin-2 / genetics. Gene Expression Regulation, Neoplastic. Hedgehog Proteins / metabolism. Skin Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • (PMID = 19914214.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endothelin-2; 0 / Gli protein, mouse; 0 / Hedgehog Proteins; 0 / Kruppel-Like Transcription Factors; 0 / RNA, Messenger
  •  go-up   go-down


80. Celić D, Lipozencić J, Jurakić Toncić R, Ledić-Drvar D, Marasović D, Puizina-Ivić N, Cabrijan L, Bradamante M: The incidence of basal cell carcinoma in Croatia: an epidemiological study. Acta Dermatovenerol Croat; 2009;17(2):108-12
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of basal cell carcinoma in Croatia: an epidemiological study.
  • The aim of the study was to investigate the basal cell carcinoma (BCC) incidence in Croatia in the 2003-2005 period.
  • Data were collected from University Department of Dermatology and Venereology, Zagreb University Hospital Center and National Cancer Registry.
  • In the study period, there were 7,244 BCC cases (3,519 men and 3,725 women) in Croatia.
  • The head and neck were almost exclusive localizations of BCC.
  • The highest BCC incidence was recorded in Zadar County.
  • The incidence of BCC was high in both littoral and inland counties of Croatia.
  • Study results will serve as reference figures on studying the trend of BCC incidence in Croatia and Europe in the forthcoming years.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Skin Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19595266.001).
  • [ISSN] 1330-027X
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


81. Uzquiano MC, Prieto VG, Nash JW, Ivan DS, Gong Y, Lazar AJ, Diwan AH: Metastatic basal cell carcinoma exhibits reduced actin expression. Mod Pathol; 2008 May;21(5):540-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma exhibits reduced actin expression.
  • Basal cell carcinoma is the most common malignancy in Caucasian individuals.
  • Metastatic basal cell carcinoma is extremely rare (with a rate estimated as 0.03%).
  • Actin has been detected in aggressive forms of basal cell carcinoma, but their expression in metastatic lesions is not known.
  • We compared the expression of actin and actin-related cytoskeletal proteins in relatively less aggressive basal cell carcinoma (nodular), aggressive basal cell carcinoma (infiltrative/morpheaform), and metastatic basal cell carcinoma.
  • We studied 12 cases of nodular basal cell carcinoma, 10 cases of infiltrative basal cell carcinoma, and 10 cases of metastatic basal cell carcinoma with immunohistochemistry for alpha-smooth muscle actin, calponin, myosin, and E-cadherin.
  • Five of the ten patients with metastatic basal cell carcinoma had an antecedent history of radiotherapy.
  • Actin was present in 3 of 12 (25%) of the nodular, all 10 of the infiltrative, and 3 of 10 of the metastatic basal cell carcinomas (P<0.05 for metastatic vs infiltrative and nodular vs infiltrative).
  • Calponin was present in 50% of the nodular, 60% of the infiltrative, and 30% of the metastatic basal cell carcinomas (not statistically significant).
  • Myosin expression was not detected in any of the cases.
  • E-cadherin was present in 75% of the nodular, 70% of the infiltrative, and all of the metastatic basal cell carcinomas (P<0.05 for metastatic vs nodular).
  • [MeSH-major] Actins / biosynthesis. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Neoplasm Invasiveness. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18223552.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Cadherins; 0 / Calcium-Binding Proteins; 0 / Microfilament Proteins; 0 / calponin; EC 3.6.4.1 / Myosins
  •  go-up   go-down


82. Jankovic I, Kovacevic P, Visnjic M, Jankovic D, Binic I, Jankovic A: Does incomplete excision of basal cell carcinoma of the eyelid mean tumor recurrence? An Bras Dermatol; 2010 Nov-Dec;85(6):872-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does incomplete excision of basal cell carcinoma of the eyelid mean tumor recurrence?
  • INTRODUCTION: Basal cell carcinoma is the most common tumor of the eyelid.
  • In this region, reconstruction is complex and damage to healthy tissue should be minimal.
  • OBJECTIVE: To define the relationship between margin clearance at excision and the recurrence rate of basal cell carcinoma of the eyelid.
  • METHODS: This prospective study was conducted with 111 patients submitted to surgery for basal cell carcinoma of the eyelid between 2001 and 2003 and followed up for a period of five years.
  • RESULTS: No significant association was found between incomplete tumor excision and recurrence except in patients under 56 years of age, female patients and in the case of tumors of the medial canthus.
  • CONCLUSION: A risk of recurrence in incompletely excised basal cell carcinomas of the eyelid was only confirmed in younger patients, females and for tumors of the medial canthus.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Mohs Surgery / methods. Neoplasm Recurrence, Local. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] An Bras Dermatol. 2011 Mar-Apr;86(2):401; author reply 401-3 [21603839.001]
  • (PMID = 21308312.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


83. Stoecker WV, Gupta K, Shrestha B, Wronkiewiecz M, Chowdhury R, Stanley RJ, Xu J, Moss RH, Celebi ME, Rabinovitz HS, Oliviero M, Malters JM, Kolm I: Detection of basal cell carcinoma using color and histogram measures of semitranslucent areas. Skin Res Technol; 2009 Aug;15(3):283-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of basal cell carcinoma using color and histogram measures of semitranslucent areas.
  • BACKGROUND: Semitranslucency, defined as a smooth, jelly-like area with varied, near-skin-tone color, can indicate a diagnosis of basal cell carcinoma (BCC) with high specificity.
  • This study sought to analyze potential areas of semitranslucency with histogram-derived texture and color measures to discriminate BCC from non-semitranslucent areas in non-BCC skin lesions.
  • METHODS: For 210 dermoscopy images, the areas of semitranslucency in 42 BCCs and comparable areas of smoothness and color in 168 non-BCCs were selected manually.
  • Six color measures and six texture measures were applied to the semitranslucent areas of the BCC and the comparable areas in the non-BCC images.
  • RESULTS: Receiver operating characteristic (ROC) curve analysis showed that the texture measures alone provided greater separation of BCC from non-BCC than the color measures alone.
  • CONCLUSION: Texture and color analysis measures, especially smoothness, may afford automatic detection of BCC images with semitranslucency.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Image Anal. 2003 Mar;7(1):47-64 [12467721.001]
  • [Cites] Skin Res Technol. 2003 Feb;9(1):73-80 [12535288.001]
  • [Cites] J Am Acad Dermatol. 2003 May;48(5):679-93 [12734496.001]
  • [Cites] Comput Med Imaging Graph. 2003 Sep-Oct;27(5):387-96 [12821032.001]
  • [Cites] Dermatology. 2004;208(1):21-6 [14730232.001]
  • [Cites] Stud Health Technol Inform. 2002;90:509-13 [15460746.001]
  • [Cites] Arch Dermatol. 2009 Feb;145(2):224 [19221287.001]
  • [Cites] Comput Med Imaging Graph. 1992 May-Jun;16(3):191-7 [1623494.001]
  • [Cites] Comput Med Imaging Graph. 1998 Sep-Oct;22(5):375-89 [9890182.001]
  • [Cites] Skin Res Technol. 2005 Aug;11(3):179-84 [15998328.001]
  • [Cites] Arch Dermatol. 2006 Sep;142(9):1211-2 [16983009.001]
  • [Cites] Arch Dermatol. 2007 Mar;143(3):329-38 [17372097.001]
  • [Cites] Comput Med Imaging Graph. 2008 Dec;32(8):670-7 [18804955.001]
  • [Cites] Comput Biomed Res. 1984 Jun;17(3):241-7 [6375947.001]
  • (PMID = 19624424.001).
  • [ISSN] 1600-0846
  • [Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  • [ISO-abbreviation] Skin Res Technol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R44 CA101639; United States / NCI NIH HHS / CA / R44 CA101639-02A2; United States / NCI NIH HHS / CA / R44 CA-101639-02A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS132816; NLM/ PMC3154079
  •  go-up   go-down


84. Star WM, van't Veen AJ, Robinson DJ, Munte K, de Haas ER, Sterenborg HJ: Topical 5-aminolevulinic acid mediated photodynamic therapy of superficial basal cell carcinoma using two light fractions with a two-hour interval: long-term follow-up. Acta Derm Venereol; 2006;86(5):412-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical 5-aminolevulinic acid mediated photodynamic therapy of superficial basal cell carcinoma using two light fractions with a two-hour interval: long-term follow-up.
  • Photodynamic therapy (PDT) of superficial basal cell carcinoma using topical 5-aminolaevulinic acid (ALA) and 75-100 J/cm2 light dose yields unsatisfactory long-term results.
  • Fifteen patients with a total of 86 primary superficial basal cell carcinomas, received topical ALA and were illuminated 4 and 6 h later, both with 45 J/cm2 laser light (633+/-1 nm).
  • There was no correlation between protoporphyrin fluorescence and response, but a significant correlation between the percentage of fluorescence left after photobleaching by the first illumination and the amount of protoporphyrin re-synthesized 2 h later.
  • In conclusion, the long-term complete remission rate of fractionated ALA-mediated PDT of superficial basal cell carcinoma as reported here is significantly better than after PDT with single illumination previously reported by others, but equal to studies using single illumination with a much higher light fluence.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Carcinoma, Basal Cell / drug therapy. Photochemotherapy / methods. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16955185.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


85. Sarfati B, Lazar CC, Goubin I, Zwillinger N, Lorenceau B: [Basal-cell carcinoma of fingers: a rare location not to be ignored]. Ann Chir Plast Esthet; 2010 Feb;55(1):74-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal-cell carcinoma of fingers: a rare location not to be ignored].
  • [Transliterated title] Epithélioma basocellulaire des doigts: une localisation rare à ne pas ignorer.
  • The basal-cell carcinoma is the most frequent malignant tumor in human, usually involving the healthy sun-exposed skin of head and neck area, but thoracic and members localisations are possible.
  • Periungual lesions are in this context very rare and we report the case of a 64-year-old man presenting with a basal-cell carcinoma on the thumb.
  • A literature review was also performed and our purpose is to warn our colleagues about this quite often unrecognized pathology which may need a more aggressive treatment in case of delayed diagnosis, and to remind them that all chronic lesions impose a biopsy.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Fingers / pathology. Fingers / surgery. Skin Neoplasms / pathology. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 Elsevier Masson SAS. All rights reserved.
  • (PMID = 19223107.001).
  • [ISSN] 1768-319X
  • [Journal-full-title] Annales de chirurgie plastique et esthétique
  • [ISO-abbreviation] Ann Chir Plast Esthet
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


86. Tang JY, So PL, Epstein EH Jr: Novel Hedgehog pathway targets against basal cell carcinoma. Toxicol Appl Pharmacol; 2007 Nov 1;224(3):257-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel Hedgehog pathway targets against basal cell carcinoma.
  • The Hedgehog signaling pathway plays a key role in directing growth and patterning during embryonic development and is required in vertebrates for the normal development of many structures, including the neural tube, axial skeleton, skin, and hair.
  • Aberrant activation of the Hedgehog (Hh) pathway in adult tissue is associated with the development of basal cell carcinoma (BCC), medulloblastoma, and a subset of pancreatic, gastrointestinal, and other cancers.
  • This review will provide an overview of what is known about the mechanisms by which activation of Hedgehog signaling leads to the development of BCCs and will review two recent papers suggesting that agents that modulate sterol levels might influence the Hh pathway.
  • Thus, sterols may be a new therapeutic target for the treatment of BCCs, and readily available agents such as statins (HMG-CoA reductase inhibitors) or vitamin D might be helpful in reducing BCC incidence.
  • [MeSH-major] Carcinoma, Basal Cell / prevention & control. Hedgehog Proteins / physiology. Signal Transduction / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):90-2 [9422511.001]
  • [Cites] Arch Dermatol. 2000 Feb;136(2):179-84 [10677093.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):216-7 [10700170.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3438-43 [10725363.001]
  • [Cites] Cell Mol Life Sci. 2000 Nov;57(12):1709-19 [11130177.001]
  • [Cites] Nutr Cancer. 2000;38(1):65-73 [11341047.001]
  • [Cites] Arch Dermatol. 2001 Sep;137(9):1162-8 [11559211.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):8-18 [11684447.001]
  • [Cites] Genes Dev. 2001 Dec 1;15(23):3059-87 [11731473.001]
  • [Cites] Oncogene. 2001 Nov 22;20(53):7770-8 [11753655.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4773-80 [12183437.001]
  • [Cites] Nature. 2002 Aug 22;418(6900):892-7 [12192414.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14071-6 [12391318.001]
  • [Cites] Genes Dev. 2002 Nov 1;16(21):2743-8 [12414725.001]
  • [Cites] Carcinogenesis. 2002 Dec;23(12):2103-9 [12507934.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):508-13 [12652302.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4616-21 [12679522.001]
  • [Cites] Methods Mol Biol. 2003;222:85-95 [12710681.001]
  • [Cites] EMBO J. 2003 Jun 2;22(11):2741-51 [12773389.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):934-41 [14871823.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1579-82 [15071140.001]
  • [Cites] J Invest Dermatol. 2004 May;122(5):1180-7 [15140221.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):148-56 [15270884.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7545-52 [15492281.001]
  • [Cites] Lancet. 1985 Feb 9;1(8424):307-9 [2857364.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1272-5 [8145782.001]
  • [Cites] J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8 [8176018.001]
  • [Cites] Int J Cancer. 1995 Jul 17;62(2):165-9 [7622291.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2349-54 [9482888.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] J Invest Dermatol. 1998 Jun;110(6):885-8 [9620294.001]
  • [Cites] Nature. 1999 Feb 18;397(6720):617-21 [10050855.001]
  • [Cites] Lancet. 1999 Aug 28;354(9180):723-9 [10475183.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7724-31 [15520176.001]
  • [Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):306-17 [15803137.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1596-607 [16030089.001]
  • [Cites] JAMA. 2005 Aug 10;294(6):681-90 [16091570.001]
  • [Cites] Nature. 2005 Oct 13;437(7061):1018-21 [16136078.001]
  • [Cites] Cochrane Database Syst Rev. 2005;(4):CD003697 [16235336.001]
  • [Cites] N Engl J Med. 2005 Nov 24;353(21):2262-9 [16306523.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):930-42 [16341084.001]
  • [Cites] Am J Public Health. 2006 Feb;96(2):252-61 [16380576.001]
  • [Cites] Dev Cell. 2006 Feb;10(2):187-97 [16459298.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):682-6 [16496410.001]
  • [Cites] J Am Acad Dermatol. 2006 Jun;54(6):933-46; quiz 947-50 [16713450.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 30;103(22):8408-13 [16707575.001]
  • [Cites] Exp Dermatol. 2006 Sep;15(9):667-77 [16881963.001]
  • [Cites] Exp Dermatol. 2006 Sep;15(9):742-50 [16881970.001]
  • [Cites] PLoS Biol. 2006 Jul;4(8):e232 [16895439.001]
  • [Cites] Nat Rev Drug Discov. 2006 Dec;5(12):1026-33 [17139287.001]
  • [Cites] Nature. 1996 Oct 3;383(6599):407-13 [8837770.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] J Natl Cancer Inst. 1996 Oct 2;88(19):1375-82 [8827015.001]
  • [Cites] Nat Med. 1997 Jul;3(7):788-92 [9212109.001]
  • [Cites] Science. 1997 Aug 22;277(5329):1109-13 [9262482.001]
  • [Cites] Nature. 1997 Oct 23;389(6653):876-81 [9349822.001]
  • [Cites] Nat Cell Biol. 1999 Sep;1(5):312-9 [10559945.001]
  • (PMID = 17276471.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / KL2 RR024130; United States / NCRR NIH HHS / RR / KL2 RR024130; United States / NCRR NIH HHS / RR / KL2 RR024130-01; United States / NCRR NIH HHS / RR / KL2 RR024130-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Sterols; 0 / Vitamins; 1406-16-2 / Vitamin D
  • [Number-of-references] 60
  • [Other-IDs] NLM/ NIHMS33795; NLM/ PMC2719777
  •  go-up   go-down


87. Motomura H, Taniguchi T, Harada T, Muraoka M, Ishii M: Aggressive basal cell carcinoma in the nasal region. J Dermatol; 2005 Jun;32(6):424-31
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive basal cell carcinoma in the nasal region.
  • It is extremely rare for basal cell carcinoma (BCC) to metastasize, so it is often only simply excised.
  • However, BCC may cause severe local tissue destruction, which often extends to surrounding muscle, cartilage, and bone; it is then termed "aggressive" BCC.
  • We evaluated the safety margin and the reconstruction method in four cases of nasal BCC that were diagnosed as aggressive BCC histopathologically or by imaging, including magnetic resonance imaging (MRI) and computerized tomography (CT) and then treated by excision.
  • The results showed that the larger the aggressive BCC was, the smaller the histopathological safety margins became.
  • Nasal BCC should be closely examinated, it requires a careful treatment strategy similar to that for other malignant skin tumors.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Neoplasm Invasiveness / pathology. Skin Neoplasms / pathology. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Mohs Surgery / methods. Neoplasm Staging. Nose. Reconstructive Surgical Procedures. Surgical Flaps. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16043913.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


88. Fernandes H, Fernandes N, Bhattacharya S, Chen W, Seth A, Hameed M, Mirani N, Lambert WC: Molecular signatures linked with aggressive behavior in basal cell carcinoma: a report of 6 cases. Am J Dermatopathol; 2010 Aug;32(6):550-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular signatures linked with aggressive behavior in basal cell carcinoma: a report of 6 cases.
  • A small subset of basal cell carcinoma (BCC) characterized by rapid growth, recurrence, deep local invasiveness to dura, and/or bone is classified as extremely aggressive.
  • Histologically, exclusive of invasive sites these tumors are similar to nonaggressive BCC.
  • Twenty-one BCC specimens, 6 aggressive and 15 nonaggressive, were used in the study.
  • LOH at one or more markers was observed in all 6 of the aggressive specimens compared with 2 of the 15 nonaggressive BCC specimens.
  • A total of 63.6% of all heterozygous markers in the aggressive tumors showed LOH compared with 17.9% of the nonaggressive BCC.
  • The tumor necrosis factor alpha -238 SNP and the interleukin 10 -1082 SNP were more prevalent in aggressive BCC.
  • The results of this pilot study indicate that LOH at chromosome 9q22 is a potential marker for the identification of aggressive behavior in BCCs.
  • Furthermore, our study suggests that cytokine SNPs may be used to stratify risk in the assessment of aggressiveness in BCC.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / genetics. Gene Expression Regulation, Neoplastic. Loss of Heterozygosity. Skin Neoplasms / diagnosis. Skin Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / genetics. Chromosomes, Human, Pair 9. DNA, Neoplasm / analysis. Female. Humans. Interleukin-10 / genetics. Male. Middle Aged. Neoplasm Invasiveness. Pilot Projects. Polymorphism, Single Nucleotide. Prognosis. Receptors, Cell Surface / genetics. Tumor Necrosis Factor-alpha / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20489570.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / IL10 protein, human; 0 / Receptors, Cell Surface; 0 / Tumor Necrosis Factor-alpha; 0 / patched receptors; 130068-27-8 / Interleukin-10
  •  go-up   go-down


89. Hoppenheit C, Hüttenberger D, Foth HJ, Spitzer WJ, Reichert TE, Müller-Richter UD: Pharmacokinetics of the photosensitizers aminolevulinic acid and aminolevulinic acid hexylester in oro-facial tumors embedded in the chorioallantois membrane of a hen's egg. Cancer Biother Radiopharm; 2006 Dec;21(6):569-78
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetics of the photosensitizers aminolevulinic acid and aminolevulinic acid hexylester in oro-facial tumors embedded in the chorioallantois membrane of a hen's egg.
  • BACKGROUND: Oral squamous-cell carcinoma is a frequent form of cancer in the head and neck region.
  • Therapy success is highly dependent on the stage of cancer development at which diagnosis is made.
  • The disease is mostly diagnosed at a late stage.
  • Photodynamic diagnosis is a new tool for screening examinations.
  • METHODS: Tumor specimens were harvested from oral carcinomas and basaliomas of the face.
  • The vital cells of the specimens and the human tumor cell line (CLS- 354) were cultured in a 90% RPMI and 10% fetal bovine serum medium.
  • A constant number of 50,000 cells from each specimen and the cell line were transferred to an in vivo model on the hen's egg model.
  • The intensity of tumor fluorescence during the following 24 hours was measured spectroscopically as the degree of concentration of protoporphyrin IX within the cells.
  • Using h-ALA, the peak concentration of protoporphyrin IX was achieved 20%-25% more quickly with 3- or 6-mM solutions than with ALA.
  • The highest contrast between tumorous and healthy tissue achieved owing to fluorescence was 1:11 using h-ALA, compared to 1:5 using ALA with the peak concentrations of protoporphyrin IX.
  • CONCLUSIONS: Using h-ALA, the peak concentration of protoporphyrin IX, compared to ALA, is achieved 20% percent more quickly and with twice as much contrast between tumorous and healthy tissue (1:11 compared and 1:5, respectively).
  • [MeSH-major] Aminolevulinic Acid / pharmacokinetics. Aminolevulinic Acid / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Chorioallantoic Membrane / drug effects. Mouth Neoplasms / drug therapy. Photosensitizing Agents / pharmacokinetics. Photosensitizing Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17257072.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Esters; 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


90. Li X, Gast A, Rudnai P, Gurzau E, Koppova K, Hemminki K, Kumar R: ARLTS1 polymorphisms and basal cell carcinoma of the skin. Hered Cancer Clin Pract; 2007;5(1):25-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ARLTS1 polymorphisms and basal cell carcinoma of the skin.
  • Polymorphisms in the ARLTS1 gene, a member of the Ras super-family, have been associated with susceptibility in different cancer types.
  • The involvement of the gene in apoptotic signalling motivated us to study the role of ARLTS1 polymorphic variations in basal cell carcinoma of the skin (BCC).
  • In a case-control study, 529 cases diagnosed with BCC and 533 controls from Hungary, Romania and Slovakia were genotyped for the S99S (297G>A), P131L (392C>T), L132L (396G>C), C148R (442T>C) and W149X (446G>A) polymorphisms in the ARLTS1 gene.
  • No significant association between any of the single nucleotide polymorphisms (SNP) and risk of BCC (S99S, odds ratio (OR) 0.96, 95% confidence interval (CI) 0.601.53; P131L, OR 1.31 95%CI 0.742.31; L132L, OR 0.50, 95%CI 0.027.07; C148R, OR 0.50, 95%CI 0.691.18; and W149X, OR 1.01, 95%CI 0.372.79) was detected.
  • Furthermore, no significant difference in the distribution of haplotypes due to five polymorphisms in the ARLTS1 gene was found between the BCC cases and controls.
  • Our data rule out an association between variants in ARLTS1 and risk of BCC in the investigated population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med Genet C Semin Med Genet. 2004 Nov 15;131C(1):82-92 [15468170.001]
  • [Cites] J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):468-73 [15761425.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10287-91 [17079447.001]
  • [Cites] Leuk Res. 2006 Dec;30(12):1573-6 [16581122.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):231-7 [15738985.001]
  • [Cites] Semin Cancer Biol. 2004 Feb;14(1):63-9 [14757536.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):23-35 [14681688.001]
  • [Cites] Arch Dermatol. 2001 Nov;137(11):1486-92 [11708952.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):19-27 [11684448.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6640-8 [11559527.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2870-7 [11306461.001]
  • [Cites] Am J Epidemiol. 2001 Mar 15;153(6):559-65 [11257063.001]
  • [Cites] Cancer Lett. 2006 Dec 8;244(2):172-5 [16488076.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1736-7 [16646072.001]
  • [Cites] Breast Cancer Res Treat. 2006 Sep;99(1):59-62 [16570116.001]
  • [Cites] Carcinogenesis. 2006 Aug;27(8):1676-81 [16501254.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2505-8 [16353159.001]
  • [Cites] N Engl J Med. 2005 Apr 21;352(16):1667-76 [15843669.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):850-60 [15516958.001]
  • (PMID = 19723348.001).
  • [ISSN] 1897-4287
  • [Journal-full-title] Hereditary cancer in clinical practice
  • [ISO-abbreviation] Hered Cancer Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC2736660
  •  go-up   go-down


91. Chai L, Tang J: [Analysis of 41 cases of basal cell carcinoma in maxillofacial area]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2006 Apr;20(7):297-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of 41 cases of basal cell carcinoma in maxillofacial area].
  • OBJECTIVE: To explore the incidence, location and relationship between surgical margin and metastasis of basal cell carcinoma (BCC) in maxillofacial area.
  • METHOD: Retrospective study was undertaken of 41 cases of BCCs in the maxillofacial region diagnosed in histopathology during the period of 1996 to 2003.
  • RESULT: From 1996 to 2003, there were 41 cases of primary BBC in maxillofacial region, of whom 17 were males and 24 were females (male-to-female ratio, 1:1.41).
  • The age of BCCs patients was between 55-74 years old, the average age of female patients was 68.1 years old, and that of the male was 58.4 years old.
  • The lesions of BCCs were found in 13 cases in the nose (31.7%), 8 cases in scalp skin (19.5%), 7 cases in periorbital skin (17.1%), 7 cases in perioral region (17.1%), 4 cases in cheek skin (9.8%) and 2 cases in auricle skin (4.89%).
  • Of all the 41 patients, 4 patients were found to suffer regional lymph nodes metastasis or local bone destruction at the first visit (9.8%), 3 patients (7.3%) had a recurrent BCC.
  • [MeSH-major] Carcinoma, Basal Cell. Facial Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780141.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


92. Karagas MR, Nelson HH, Zens MS, Linet M, Stukel TA, Spencer S, Applebaum KM, Mott L, Mabuchi K: Squamous cell and basal cell carcinoma of the skin in relation to radiation therapy and potential modification of risk by sun exposure. Epidemiology; 2007 Nov;18(6):776-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell and basal cell carcinoma of the skin in relation to radiation therapy and potential modification of risk by sun exposure.
  • BACKGROUND: Epidemiologic studies consistently find enhanced risk of basal cell carcinoma of the skin among individuals exposed to ionizing radiation, but it is unclear whether the radiation effect occurs for squamous cell carcinoma.
  • METHODS: We analyzed data from a case-control study of keratinocyte cancers in New Hampshire.
  • Incident cases diagnosed in 1993-1995 and 1997-2000 were identified through a state-wide skin cancer surveillance system, and controls were identified through the Department of Transportation and Center for Medicare and Medicaid Service Files (n = 1121 basal cell carcinoma cases, 854 squamous cell carcinoma cases, and 1049 controls).
  • RESULTS: We found an association between history of radiation treatment and basal cell carcinoma.
  • The association was especially strong for basal cell carcinomas arising within the radiation treatment field (odds ratio = 2.6; 95% confidence interval = 1.5-4.3), and among those treated with radiation therapy before age 20 (3.4; 1.8-6.4), those whose basal cell carcinomas occurred 40 or more years after radiation treatment (3.2; 1.8-5.8), and those treated with radiation for acne (11; 2.7-49).
  • Similar age and time patterns of risk were observed for squamous cell carcinoma, although generally with smaller odds ratios.
  • For basal cell carcinoma, early exposure to radiation treatment was a risk factor largely among those without a history of severe sunburns, whereas for squamous cell carcinoma, radiation treatment was a risk factor primarily among those with a sun-sensitive skin type (ie, a tendency to sunburn).
  • CONCLUSIONS: Radiation treatment, particularly if experienced before age 20, seems to increase the long-term risk of both basal and squamous cell carcinomas of the skin.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17917604.001).
  • [ISSN] 1044-3983
  • [Journal-full-title] Epidemiology (Cambridge, Mass.)
  • [ISO-abbreviation] Epidemiology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA082354; United States / NCI NIH HHS / CA / CA23108; United States / NCI NIH HHS / CA / CA57494; United States / NCI NIH HHS / CA / CA58290
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


93. Maksimović N, Raznatović M, Marinković J, Janković J: [Exposure to sun radiation as a risk factor for the occurrence of basal cell carcinoma in the Montenegrian population]. Vojnosanit Pregl; 2006 Jul;63(7):643-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Exposure to sun radiation as a risk factor for the occurrence of basal cell carcinoma in the Montenegrian population].
  • BACKGROUND/AIM: [corrected] Basal cell carcinoma (BCC) is the most frequent form of carcinomas in the whites.
  • The aim of this study was to assess the role of the sun radiation in the development of basal cell carcinoma BCC in the Montenegrian population.
  • METHODS: A case-control study was conducted in a period from 2002-2003.
  • The study group included 100 histopatologically confirmed cases with BCC, while the control group included 100 patients from the same population, who did not present skin cancer and who were individually matched with the cases from the study group by sex and age (+/- 5 years).
  • RESULTS: The risk for development of BCC was increased in the persons: that always had burns with no tan during the exposure to sunlight (OR = 1.75; 95% CI = 1.20-2.55; p = 0.003); that developed sunburns after two hours of the exposure to sunlight (OR = 3.72; 95% CI = 2.39-5.79; p < 0.001) that kept light tan or remained without changes in childhood and adolescence after the repeated exposures to sunlight (OR = 2.92; 95% CI = 1.89-4.52; p < 0.001) that often had severe and painful sunburns (OR = 4.48; 95% CI = 2.74-7.33; p < 0.001).
  • CONCLUSION: Our study confirmed the significance of sunlight exposure for the development of BCC.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Neoplasms, Radiation-Induced. Skin Neoplasms / etiology. Sunlight / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875424.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


94. Taboada A, Prieto A, Couto I, Brea B, González E: [Invasive basal cell carcinoma of the scalp. A clinical case]. Neurocirugia (Astur); 2010 Oct;21(5):396-400
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Invasive basal cell carcinoma of the scalp. A clinical case].
  • [Transliterated title] Carinoma basocelular invasivo de cuero cabelludo. Caso clínico.
  • Basal cell carcinoma is the most frequent skin malignant neoplasm, although it doesn't usually compromise a vital risk.
  • However, there are cases in which their local aggressiveness is very important, and it get deep structures.
  • We present a 62 years old female operated several times because multifocal basal cell carcinoma on her scalp.
  • We show the clinical case and the surgical treatment employed realized by Plastic and Neurosurgery Departments.
  • [MeSH-major] Brain Neoplasms. Carcinoma, Basal Cell. Head and Neck Neoplasms. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21042691.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


95. Christensen E, Bofin A, Gudmundsdóttir I, Skogvoll E: Cytological diagnosis of basal cell carcinoma and actinic keratosis, using Papanicolaou and May-Grünwald-Giemsa stained cutaneous tissue smear. Cytopathology; 2008 Oct;19(5):316-22
Hazardous Substances Data Bank. METHYLENE BLUE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological diagnosis of basal cell carcinoma and actinic keratosis, using Papanicolaou and May-Grünwald-Giemsa stained cutaneous tissue smear.
  • OBJECTIVE: Cytology may become the diagnostic method of choice with the advent of new non-invasive treatments for non-melanoma skin cancer, as the sampling technique for cytology entails little tissue disfiguration.
  • The aim of this study was to compare and evaluate the diagnostic performance of scrape cytology using two different cytological staining techniques, and to evaluate additional touch imprint cytology, with that of histopathology of basal cell carcinoma (BCC) and actinic keratosis (AK).
  • METHODS: We investigated 50 BCC and 28 AK histologically verified lesions, from 41 and 25 patients, respectively.
  • Two separate skin scrape samples and one touch imprint sample were taken from each lesion.
  • RESULTS: Scrape cytodiagnosis agreed with histopathology in 48 (Pap) and 47 (MGG) of the 50 BCC cases, and in 26 of 28 (Pap) and 21 of 26 (MGG) AK cases, yielding sensitivities of 96%, 94%, 93% and 81%, respectively.
  • Touch imprint cytology confirmed histopathology in 38 of the 77 cases of BCC and AK.
  • CONCLUSION: Cytological diagnosis with either Pap or MGG stain for BCC and AK is reliable, and differentiates well between BCC and AK.
  • Imprint cytology proved to be non-diagnostic in half of the examined cases.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Coloring Agents. Cytodiagnosis / methods. Eosine Yellowish-(YS) / metabolism. Keratosis / diagnosis. Methylene Blue / metabolism. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cytopathology. 2008 Oct;19(5):333-4; author reply 334 [18513288.001]
  • (PMID = 17916094.001).
  • [ISSN] 1365-2303
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / May-Grunwald Giemsa; T42P99266K / Methylene Blue; TDQ283MPCW / Eosine Yellowish-(YS)
  •  go-up   go-down


96. Hellani A, Baghdadi H, Dabbour N, Almassri N, Abu-Amero KK: A novel PTCH1 germline mutation distinguishes basal cell carcinoma from basaloid follicular hamartoma: a case report. J Med Case Rep; 2009;3:52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel PTCH1 germline mutation distinguishes basal cell carcinoma from basaloid follicular hamartoma: a case report.
  • INTRODUCTION: Nevoid basal cell carcinoma syndrome is a rare autosomal dominant disorder characterized by numerous basal cell carcinomas, odontogenic keratocysts of the jaws and developmental defects.
  • The disorder results from mutations in the PTCH1 gene.
  • CASE PRESENTATION: A 15-year-old boy presented to our dental clinic with multiple jaw cysts.
  • Examination of the jaw cysts revealed many keratinizing cysts without granular cell layers a finding that raised the suspicion of nevoid basal cell carcinoma.
  • These features make it difficult to differentiate between nevoid basal cell carcinoma and basaloid follicular hamartoma, especially the presence of these findings on a non-hairy area.
  • BCL-2 staining was positive in the periphery of the basaloid proliferation, which is typical of basaloid follicular hamartoma, and not in a diffuse pattern, which is typical of nevoid basal cell carcinoma.
  • Since histology was equivocal and palmoplantar pits are seen in both basaloid follicular hamartoma and nevoid basal cell carcinoma, molecular genetic investigation was necessary to differentiate between the two potential diagnoses.
  • This de novo mutation was not detected in both parents and in 100 normal volunteers of matching ethnicity.
  • CONCLUSION: Screening the PTCH1 gene for mutations helped to differentiate between basaloid follicular hamartoma and nevoid basal cell carcinoma and confirmed the diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cutan Pathol. 2008 May;35(5):477-83 [18399809.001]
  • [Cites] Oral Dis. 2008 Mar;14(2):174-9 [18302678.001]
  • [Cites] Hum Mutat. 2006 Mar;27(3):215-9 [16419085.001]
  • [Cites] Development. 1998 Aug;125(15):2803-11 [9655803.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):757-62 [11257109.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):78-81 [8782823.001]
  • [Cites] Dermatol Clin. 1995 Jan;13(1):113-25 [7712637.001]
  • [Cites] Hum Mutat. 2003 Jun;21(6):577-81 [12754702.001]
  • [Cites] Nature. 1996 Nov 14;384(6605):129-34 [8906787.001]
  • (PMID = 19203369.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2642855
  •  go-up   go-down


97. Leyngold M, Leyngold I, Letourneau PR, Zamboni WA, Shah H: Basal cell carcinoma and rhinophyma. Ann Plast Surg; 2008 Oct;61(4):410-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma and rhinophyma.
  • Basal cell carcinoma (BCC) is a rare finding in patients with rhinophyma.
  • The objective of this study is to review the literature of BCC in rhinophyma and report on a case.
  • Since 1955 there have been 11 cases reported in the literature.
  • In our case, the pathology report noted that the specimen had an incidental finding of a completely resected BCC.
  • Despite the uncommon occurrence of BCC in resection specimens for rhinophyma, we recommend that all specimens be reviewed by a pathologist.
  • If BCC is detected, re-excision may be necessary and careful follow-up is mandatory.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Nose Deformities, Acquired / surgery. Nose Neoplasms / surgery. Precancerous Conditions / surgery. Rhinophyma / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Cell Transformation, Neoplastic. Humans. Male. Nose / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812712.001).
  • [ISSN] 1536-3708
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Almeida AC, Yamashita T, Conte B, Mattos AC, Veríssimo RP, Ferreira MC: [Frequency of basal cell carcinoma in a population younger than 50 years of age: clinical study and literature review]. An Bras Dermatol; 2009 Nov-Dec;84(6):692-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Frequency of basal cell carcinoma in a population younger than 50 years of age: clinical study and literature review].
  • [Transliterated title] Frequência do carcinoma basocelular na população menor de 50 anos: estudo do serviço e revisão de literatura.
  • Basal cell carcinoma is the most common type of malignant cutaneous neoplasm in humans, and it can be prevented and diagnosed early.
  • The purpose of this study is to present clinical and microscopic findings of basal cell carcinoma in a population younger than 50 years of age.
  • Microscopic examinations of multiple sections of skin lesion have been done, as well as a review of relevant literature.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Skin Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20191187.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Brazil
  • [Number-of-references] 10
  •  go-up   go-down


99. Bordel-Gómez MT, Miranda-Romero A: [Post-traumatic basal cell carcinoma associated with patch testing]. Actas Dermosifiliogr; 2009 Sep;100(7):606-10
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Post-traumatic basal cell carcinoma associated with patch testing].
  • [Transliterated title] Carcinoma basocelular postraumático relacionado con pruebas epicutáneas.
  • Basal cell carcinoma is the most common epithelial skin cancer in humans and usually effects elderly individuals.
  • We present the case of a woman with contact dermatitis due to sensitization to metals.
  • She developed superficial basal cell carcinoma at the same site as a patch test-performed 30 months earlier-that was strongly positive to 1 % gold chloride.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Patch Tests / adverse effects. Skin Neoplasms / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19715646.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


100. Drakaki E, Kaselouris E, Makropoulou M, Serafetinides AA, Tsenga A, Stratigos AJ, Katsambas AD, Antoniou C: Laser-induced fluorescence and reflectance spectroscopy for the discrimination of basal cell carcinoma from the surrounding normal skin tissue. Skin Pharmacol Physiol; 2009;22(3):158-65
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laser-induced fluorescence and reflectance spectroscopy for the discrimination of basal cell carcinoma from the surrounding normal skin tissue.
  • The object of this study was to investigate whether laser-induced skin autofluorescence (LIF) and/or light reflectance spectra could provide a useful contrast between basal cell carcinoma (BCC) tissues and the surrounding healthy skin.
  • Unstained human skin samples, excised from humans undergoing biopsy examination, were irradiated with a nitrogen laser (lambda = 337 nm) for excitation of autofluorescence and a tungsten halogen lamp for the reflectance measurements.
  • The ex vivo spectroscopic results were correlated with the histopathology images to distinguish the areas of BCC from those of the surrounding health skin.
  • A simple spectral analysis technique was also applied for better skin diagnosis.
  • In conclusion, it seems that LIF and reflectance spectra could be used to differentiate neoplastic from normal skin tissue using an appropriate classification model analysis.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / pathology. Skin / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19365155.001).
  • [ISSN] 1660-5535
  • [Journal-full-title] Skin pharmacology and physiology
  • [ISO-abbreviation] Skin Pharmacol Physiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down






Advertisement